ENETS
European Neuroendocrine Tumor Society

14th Annual ENETS Conference
for the Diagnosis and Treatment of
Neuroendocrine Tumor Disease

8 - 10 March 2017 | Barcelona | Spain

Conference Program

BECOME AN ENETS MEMBER ONSITE!

You are just four steps away from becoming a member:

- Visit the registration desk
- Pay members fee € 30
- Receive a member recommendation letter
- Obtain signage by an ENETS member

YOUR BENEFITS ARE:

Reduced fee for participation in the annual conferences

Free access to the ENETS official journal *Neuroendocrinology*

Free access to webinars following ENETS conferences

Collaboration with ENETS task forces and projects:
ENETS Centers of Excellence (ENETS CoE)
ENETS European NET Registry

Applications to ENETS grants, awards and summer schools

Involvement of Young Investigator collaborative projects
(ENETS CoE Excellence Academy Fellowship)

Participation in further educational projects, earning CME points
through e-learning NET-CME programs and future ENETS webinars

Networking amongst interdisciplinary NET projects

Password-protected access to the members section 'MY ENETS'
via www.enets.org

| HOME | MEMBERSHIP | EDUCATION/CME | ANNUAL ENETS CONFERENCE | ENETS REGISTRY | NET NURSE |
| ABOUT US | ENETS GUIDLINES | | GRANTS AND AWARDS | CENTERS OF EXCELLENCE | |

Table of Contents

Legend

| Introduction | General Information | Scientific Program | CoE Workshop | Sponsors & Exhibitors |

MY ENETS

MY ENETS is a professional web portal made exclusively for ENETS members.

You can update your profile, change your conference registration data, find out how to apply as a Center of Excellence (CoE), obtain free access to Neuroendocrinology (official journal of ENETS), view past conference talks as webcasts in the media library and much more.

Please login to your ENETS member account and access **MY ENETS** via *www.enets.org/my_enets*

ENETS Aims & Key Dates

ENETS Aims

- Improve the diagnosis and therapy of patients with neuroendocrine tumors in an international, interdisciplinary and scientific context
- Coordinate research at European hospitals and health research institutes, with emphasis on basic and clinical research for the diagnosis and treatment of NETs
- Further develop standards for the accreditations of ENETS Centers of Excellence (CoE)
- Offer education and training for physicians and scientists at annual scientific and educational meetings
- Focus on writing and updating NET guidelines for all aspects of NET care including treatment and standards of care and subsequently publicizing in medical and scientific journals
- Foster the exchange of forums for young investigators
- Support collaborative scientific projects of excellence
- Communicate with and inform patient advocates and patient self-help groups
- Cooperate with the pharmaceutical industry for the development of new diagnostic, therapeutic and information technologies
- Further endorse the ENETS Registry and ENETS Centers of Excellence (CoE) throughout Europe

Current Key Dates

ENETS Centers of Excellence (CoE) Academy Fellowship Grant (EAFG) Application:
- Submission begins 1 May 2017
- Submission ends 30 June 2017

15th Annual ENETS Conference, 7-9 March 2018, Barcelona, Spain:
- ENETS Early Bird Registration begins 1 September 2017
- ENETS Early Bird Registration ends 30 November 2017
- ENETS Regular Registration begins 1 December 2017
- ENETS Regular Registration ends 11 February 2018

ENETS Abstract Submission for the 15th Annual ENETS Conference:
- Submission begins 1 September 2017
- Submission ends 3 December 2017

ENETS Travel Grant Submission for the 15th Annual ENETS Conference:
- Submission begins 1 September 2017
- Submission ends 3 December 2017

ENETS Grants and Awards Application submission begins 1 November 2017 and ends 7 January 2018:
- ENETS CoE Training Fellowship Grant
- ENETS CoE Young Investigator Grant
- ENETS Translational Grant – partially industry - sponsored
- ENETS Håkan Ahlman Award

Welcome Letter

Dear Colleagues,

On behalf of the European Neuroendocrine Tumor Society (ENETS) and its Scientific Organizing Committee, it is our great pleasure to welcome you to our 14th Annual ENETS Conference. We hope to offer the most current and relevant aspects of neuroendocrine tumor disease, diagnostics and therapeutics as well as update you on the ENETS Clinical and Surgical Trials. This 3-day meeting will include a **Postgraduate Course** (8th of March), **ENETS/NANETS Young Investigator Symposium**, **Meet the Professor** Sessions and **Nurse Workshop** (9th of March), Breakfast **Workshop 'Imaging Update'** and **Nurse Symposium** (10th of March).

Massimo Falconi
ENETS Chairman

Amongst the many other lectures, talks will cover 'Immune System and Cancer', 'Metabolic Symbiosis' as well as 'Resistance in Anti-Angiogenic Therapy'. One of the many plenary sessions will be titled 'How To Not Do Harm?' and for this session experts have been lined up to contribute their views from the different disciplinary perspectives (e.g. radiology, surgery, chemotherapy and targeted therapy). A short but insightful session will introduce ENETS surgical trials. Feedback is welcomed accordingly. This session will be followed by the 'Nurse Symposium' and 'Response Prediction and Resistance' in which ENETS is very lucky to have won highly motivated experts to convey the latest perspectives in their fields.

In addition, we are delighted that this year there will be a **Joint INCA and ENETS Symposium** taking place on Friday, 10th of March 2017, covering Unmet Medical Needs from the perspective of physicians and patients.

Moreover, ENETS is proud to award this year's **Life Achievement Award to Prof. Kjell Öberg**, who is Professor of Endocrine Oncology at the Medical Faculty of Uppsala University and one of the founders of ENETS. Ever since he introduced alpha-interferon as a treatment for neuroendocrine tumors in the early 1980s, he has devoted his professional life to development of new diagnostic methods and treatments for these patients. He is a highly respected lecturer and organized numerous courses, spreading the knowledge of neuroendocrine tumors to clinicians in every corner of the world.

The conference has been granted a total of **16 CME credits by the UEMS - EACCME®**. Each year ENETS tries to improve its program. We are happy to inform you that the **poster sessions have been lengthened** and **will include poster walks**, which is also due to the fact of having received the **highest number of abstracts ever, over 350**. We look forward to many exciting and important discourses and appreciate any **feedback from you via the learner's feedback questionnaires**, which will be offered at the terminals in the lobby throughout the conference days. I would like to thank an excellent faculty for investing their valuable time. Many thanks also go to the generous support of the sponsors, Ipsen as Platinum, Novartis as Legacy, Pfizer and AAA both as Silver sponsors. We thank Sirtex and Wisepress for exhibiting, as well as the patient organizations, the NET Patient Foundation, INCA and NET Research Foundation, as well as BioScientifica, and also to Karger who publish Neuroendocrinology, the official ENETS journal.

A more than very special thank you goes to the **ENETS Executive Committee** for their hard work, **Centers of Excellence auditors and GSG**, as well as to the **ENETS staff and the conference team** for their superb organization. We look forward to exciting conference days with you and hope you also enjoy Barcelona.

Enjoy the meeting! I always look forward to meeting and hearing your views.

Massimo Falconi
ENETS Chairman

VISIT THE ENETS BOOTH

The ENETS Booth will offer terminals for:
- Participants who wish to sign up and become an ENETS member
- Members to learn more about their membership area 'MY ENETS'

All participants can:
- View the webcasts from the Annual ENETS Conference in 2016
- Review the E-learning course NET-CME
- Use the ENETS booth as a meeting point

Learn about the different ENETS projects:
- ENETS CoE - Centers of Excellence
- ENETS NET Registry
- Grants and Awards

European Union of Medical Specialists
EACCME - European Accreditation Council for Continuing Medical Education
Institution of the UEMS
Rue de l'industrie 24, B-1040, Brussels
T: +32 2 649 5164 | **F:** +32 2 640 37 30 | **E:** accreditation@uems.eu

European Neuroendocrine Tumor Society

SUBJECT: EACCME accreditation granted EACCME-15071-G

We are pleased to inform you that your application for European accreditation for:

14th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease
Venue: Barcelona, Spain (8.–10.03.2017)

was granted **16** European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

European Accreditation
European Accreditation is granted by the EACCME in order to allow participants who attend the above-mentioned activity to validate their credits in their own country.

Accreditation Statement
Accreditation by the EACCME confers the right to place the following statement in all communication materials including the registration website, the event programme and the certificate of attendance. The following statements must be used without revision:

»The 'European Neuroendocrine Tumor Society' (or) '14th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease' is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.«

»The '14th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease' is designated for a maximum of (or 'for up to') 16 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.«

»Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.«

»Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.«

EACCME credits
Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

Logo
The UEMS – EACCME logo is a service mark of the European Union of Medical Specialists – European Accreditation Council for CME. This service mark may be used publicly only with the permission of the UEMS – EACCME. The logo may only be used in conjunction with, and in proximity to, the EACCME accreditation statement. The logo cannot be used in notices, advertising, or promotion of activities other than in association with the EACCME accreditation statement.

Feedback report
The EACCME requires you to provide a feedback report of the event within four weeks of its completion together with a copy of the list of participants and the results of the individual feedback assessments by participants.

Brussels, 6. 1. 2017   The UEMS – EACCME Secretariat

ENETS Registration Desk Location & Times

The registration desk is located on the ground floor of the CCIB.
Tuesday, 07 March   14:00 - 18:00 (Only early pre-confirmed group pick-up)
Wednesday, 08 March   08:00 - 17:30
Thursday, 09 March   07:00 - 18:00
Friday, 10 March   06:45 - 16:30

Conference Venue Address

Centro de Convenciones Internacional de Barcelona (CCIB)
GL events CCIB, SL | Willy Brandt Square 11-14 | 08019 Barcelona, Spain
www.ccib.es

ENETS Office Location & Times

The ENETS Office is located in Room 134 on the first floor of the CCIB.
Wednesday, 08 March   07:30 - 17:30
Thursday, 09 March   07:00 - 17:30
Friday, 10 March   06:45 - 16:30

ENETS Cloakroom

The cloakroom is located on the ground floor, adjacent the main entrance. Opening hours are the same as of the registration desk. It is also open for the Welcome Reception and the industry-sponsored symposia.

Industry Exhibition

Wednesday, 08 March   08:00 - 17:30
Thursday, 09 March   08:00 - 17:15
Friday, 10 March   08:45 - 16:00

Business Services, Printing Boarding Passes

The ENETS business center is located in Room 118 on the first floor. The business center has the same opening hours as the ENETS Office. Laptops and printing services, e.g. for boarding passes or any other material, are available here.

iPhone / Android Apps

An ENETS conference app will be available in the iTunes Store and the Google Play Store. Please search the stores for "ENETS" (in quotes) or scan one of the provided QR-Codes available at the app-helpdesk across the registration counter. If you need any help installing or using the app, assistance is also available there. (View page 16 and 17 for instruction overview)

ENETS Booth

The ENETS Booth will be set-up close to the registration desk and offers terminals for participants who wish to sign up and become an ENETS member and for members to find out more about their membership area 'MY ENETS'. All participants can also view the webcasts from the 13th Annual ENETS Conference in 2016, review the E-learning course NET-CME, learn about the different ENETS projects such as ENETS CoE - Centers of Excellence, ENETS Registry, Grants and Awards and use the ENETS booth as a meeting point.

Please visit the ENETS Booth!

Meet the Professor (9 March) / Nurse Workshop (9 March) / Workshop Imaging Update (10 March)

These sessions have an extra fee and should have been pre-registered for as attendance is limited. Registered participants must be present at the session room no later than 7:20 in the morning on 9 and/or 10 March 2017. No-show slots will be given to interested delegates who were assigned to a waiting list. If you signed up on the waiting list, you should be at the session room by 7:20 and must have the € 35 in cash for immediate payment.

Poster Exhibition
The Poster Exhibition will be located on the ground floor and will be open:
Wednesday, 08 March   08:00 - 17:30
Thursday, 09 March   08:00 - 18:00
Friday, 10 March   08:45 - 16:30

Please note that during the Poster Sessions A and B on 9 and 10 March 2017, there will be poster walks. Please view schedule on page 36 and 37. Participation in the poster walks are limited to 15 participants, which is offered on a first come, first serve basis.

Name Badges and Barcode-Scan for acquiring CME Points
Every ENETS conference participant will receive a name badge with a barcode. The badge must be worn at all times in the conference venue. Every badge will be scanned BOTH before the morning and afternoon lectures at the entrance to your session.

Please be aware that you will only receive your CME credits if you have been present in the conference lectures and your badge has been scanned before the morning AND/OR the afternoon session. In order to have all your achieved CME credits indicated on your certificate, please print your certificate on your last day before you leave the conference.

Distribution of the CME credits
- 6 CME points for the PG course only on 08 March
- 6 CME points for the regular full program on 9 March
- 4 CME points for the regular full program on 10 March

In order to receive the full amount of 16 CME points for 8, 9 and 10 March, you must be present in the sessions you attend and MUST make sure your badge is scanned upon entering the sessions BOTH in the morning and afternoon. If you lose your badge, please go to the registration desk to receive a new one.

Certificate of Attendance and Accreditation
Every conference delegate will receive a certificate of attendance and accreditation. This certificate is granted under the auspices of the UEMS accreditation authorities in Brussels. The accreditation shown on the certificate is based on when the participant was present in the scientific sessions, and therefore, every participant should be sure to have his or her name badge scanned upon entering both the morning and afternoon lectures.

Following the conference, participants should visit any of the certificate terminals/evaluation desks (view site map) situated in the foyer on ground floor of the conference area so as to redeem their CME points and print out their attendance/accreditation certificates. You will need to scan your badge and fill out the learner's feedback evaluation form provided to print your certificate. A detailed instruction sheet is available at the desk as well as a hostess to help with the procedure.

Conference Social Program
All registered conference delegates are cordially invited to:

ENETS Welcome Reception
Wednesday, 08 March   17:15 - 18:15
CCIB – Barcelona International Convention Centre
Please note that only conference delegates wearing a valid conference name badge will be granted access.

Learner's Feedback Evaluation Form
We urge all participants to fill out a learner's feedback evaluation form, which can be uploaded and filled at all designated terminals prior to receiving your certificate of attendance and accreditation. ENETS expresses thank you in advance for all submitted evaluation forms, as your feedback is important.

Insurance & Liability

Neither the organizers nor the Conference ENETS Office will assume any responsibility whatsoever for damage or injury to persons or property during the conference. It is recommended that participants arrange for their personal travel and health insurance.

Lost & Found

Lost & Found items can be brought to and retrieved at the cloakroom on the ground floor of the CCIB adjacent the main entrance. Opening hours are the same as of the registration desk. It is also open for the Welcome Reception and the industry-sponsored symposia.

Conference Bag

Every participant will receive a complimentary bag at the ENETS 2017 conference which is available for pick-up at the registration desk. The following items will be included: conference program, mini program, abstract booklet, post-it notes, ballpoint pen, block of paper, microfiber cleaning cloth, cotton shopping bag with the ENETS logo and a memory stick containing conference program information and the ENETS Guidelines 2016 as .pdf file (O'Toole et al., ENETS 2016 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update, Neuroendocrinology 2016, 103: 113-195).

Speakers Preview Room (Media Room)

Room 119 on the first floor of the CCIB has been designated for conference speakers to upload and preview their presentations. Please be aware that all conference speakers must have uploaded their presentations at least one hour before expected on stage. A technician to help you will be available during the ENETS Office opening hours.

Industry – Sponsored Satellite Symposia

The ENETS 2017 Annual Conference includes four symposia organized by the platinum, legacy and silver sponsors. Entry to these symposia is free of charge. Breakfast for Satellite Symposium III, Lunch boxes for Satellite Symposium I and IV and a snack for Satellite Symposium II will be provided in room 112.

The schedule is as follows:

Industry - Sponsored Satellite Symposium I:	09 March	12:45 - 14:15	Room 112	First Floor/Level P1
Industry - Sponsored Satellite Symposium II:	09 March	18:45 - 20:15	Room 112	First Floor/Level P1
Industry - Sponsored Satellite Symposium III:	10 March	07:00 - 08:30	Room 112	First Floor/Level P1
Industry - Sponsored Satellite Symposium IV:	10 March	12:50 - 14:20	Room 112	First Floor/Level P1

Exhibition

ENETS will be offering conference participants a chance to gain information and learn more about NET issues from diverse and interdisciplinary areas. ENETS welcomes all participants to visit the exhibition hall on the ground floor behind the registration desk. The floor plan of the exhibitor's hall can be viewed in the "Sponsors and Exhibitors" part from page 66 on.

Exhibitors and Sponsors

Exhibitors and sponsors may not hold satellite events during the defined "blackout" times unless approved by ENETS. ENETS will strictly enforce this policy.

The blackout times for ENETS 2017, which correspond to the conference program, are as follows:

Wednesday, 08 March	08:15 - 13:10	14:10 - 18:15
Thursday, 09 March	08:30 - 12:45	14:15 - 17:45
Friday, 10 March	08:30 - 12:50	14:20 - 16:20

ENETS also prohibits marketing research and marketing events from being conducted during the Annual Conference. ENETS encourages pharmaceutical companies to observe phRMA guidelines in determining how to interact with delegates at the Annual Conference. Specific questions related to marketing activities should be directed to the ENETS Office in Berlin.

ENETS Annual General Assembly

Every ENETS member is welcome to attend the Society's annual General Assembly meeting. Only ENETS members are allowed entry to the General Assembly meeting and only those members who have paid all their membership fees up to 2017 latest until 15:00 on 9 March 2017 are entitled to vote on any agenda items.

The General Assembly meeting will be held on Thursday, 9 March at 17:45 in Room 111, First Floor, Level P1.

Internet / WiFi access

Wireless internet access will be available in most areas.
SSID: ENETS
Password: Barcelona

Conference Organization

ENETS Conference Organization
ENETS Office
c/o Charité Universitätsmedizin Berlin
Campus Virchow-Klinikum
Hepatology and Gastroenterology
Augustenburger Platz 1
13353 Berlin, Germany

E-mail: conference@enets.org

Tel: +49-30-450 553 096
Fax: +49-30-450 553 942

ENETS Conference Website: enetsconference.org
ENETS Society Website: www.enets.org

First Floor
Level P1

111	=	General Assembly
111	=	ENETS / NANETS Young Investigator Symposium
111	=	INCA/ENETS Symposium
111	=	Parallel Sessions (2A, 3B, 4A, 8A, 9B)
112	=	Postgraduate Course
112	=	Industry-Sponsored Symposia I,II,III,IV
113	=	Main Plenary
118	=	Business Center
119	=	Speaker's Preview Room
124	=	Meet the Professor I
125	=	Meet the Professor II
127	=	Meet the Professor III
128	=	Meet the Professor IV
129	& 130	Imaging Update Workshop & Nurse Workshop
131	=	ENETS Meeting Room
133	=	ENETS AV / IT / Storage
134	=	ENETS Office

125 Meet the Professor II

124 Meet the Professor I

123

122

121

120

119 Speaker's Preview Room

118 Business Center

127 Meet the Professor III

128 Meet the Professor IV

129 Imaging Update Workshop

130 Nurse Workshop

131

132 ENETS Meeting Room

133 ENETS AV / IT / Storage

134 ENETS Office

Room 113 - 116

Main Plenary Hall

Room 112

Postgraduate Course

Industry-Sponsored Symposia I,II,III,IV

Room 111

Parallel Sessions (2A, 3B, 4A, 8A, 9B)

General Assembly ENETS / NANETS Young Investigator Symposium INCA / ENETS Symposium

Ground Floor
Level P0

Non-Profit Exhibitors:

B = Bioscientifica
N = NET Patient Foundation
6 = INCA / NET Research Foundation

ENETS:

P = Poster Help Desk / Poster Walks

Lunch &
Coffee Break
Area

Poster
Exhibition

P

B

N

5

6

7

3

4

1

2

Registration Desk

ENETS
Booth

e-Poster
Desk

e-Poster
Desk

Cloakroom

Evaluation
Desk /
Onsite
registration

Evaluation
Desk /
Onsite
registration

Evaluation
Desk /
Onsite
registration

Main Entrance

GENERAL INFORMATION

For full view of all sponsor booths, please refer to page 71

GENERAL INFORMATION

How to install the ENETS App:

For iOS devices:

1. Open the App Store by clicking on this icon:

2. Type „ENETS" in the search field and press „Search"

3. Click on „Get +" to install the App.

For Android devices:

1. Open the Google Play Store by clicking this icon:

2. Type „ENETS" (with quotes!) in the search field and press „Search".

3. Click on the first result „ENETS App" to install the App.

GENERAL INFORMATION

ENETS App Features Overview:

Click here to view and check the program for last minute updates.

Click here to learn about the ENETS conference speakers by searching or even bookmark speakers.

Click here and search for the exhibitors and find out where they are located in the exhibition hall and receive detailed information about the company.

Click here to read all the abstracts, download and retrieve a pdf-file sent to you via e-mail. You can also do a full text search to find your desired abstract.

Click here to find information about the grant and award recipients from the ENETS Grants & Awards Ceremony.

Click here to start the integrated QR Scanner. You can scan the provided QR codes next to each poster and collect the information about the poster author.

Click here to start the integrated Live Poll Tool. You can give your direct and live feedback for a talk as soon as a conference speaker or chair announces the poll number to you.

Click here to read the FAQ's about the conference, the ENETS Society or becoming an ENETS member and much more.

If you need help using the App, please ask a hostess at the App Help Desk located at the ENETS Booth right across the Registration Desk.

ENETS
European Neuroendocrine Tumor Society

SCIENTIFIC PROGRAM

Martyn Caplin
United Kingdom

Rocio Garcia-Carbonero
Spain

Wouter W. de Herder
Netherlands

Massimo Falconi
Italy

Reza Kianmanesh
France

Dermot O'Toole
Ireland

Marianne Pavel
Germany

Aurel Perren
Switzerland

Eva Tiensuu Janson
Sweden

Bertram Wiedenmann
Germany

LIFE ACHIEVEMENT AWARD 2017

Professor Kjell Öberg, MD, PhD

Kjell Öberg is Professor of Endocrine Oncology at the Medical Faculty of Uppsala University. He was the former Head of the Department of Endocrine Oncology, University Hospital, and he is a specialist in endocrinology and internal medicine. He founded the Dept. of Endocrine Oncology at Uppsala University Hospital and has 40 years of experience in the field of neuroendocrine tumors. In addition to serving as Vice-Chairman of the ENETS Executive Committee he held the position of ENETS Chairman from 2012-2014.

He also headed the first ENETS Summer School, which took place in Uppsala, Sweden in 2014. Dr. Öberg is a member of several national and international scientific societies. He is a member of the NANETS Advisory Board as well as several other national and international research and scientific boards and many scientific journal review boards. Dr Öberg has contributed with more than 500 publications in the field of NETs. He was the Chairman of the Centre of Excellence of Endocrine Tumors, Uppsala University Hospital until May 2013. At present time he is Senior Advisor/Senior Professor at the same department.

ENETS Life Achievement Award Winners and Honorary Members		
2016	Prof. Jean-Claude Reubi	SUI
2015	Dr. Robert T. Jensen	USA
2014	Prof. Eric Krenning	NED
2013	Dr. Larry Kvols	USA
2012	Prof. Steven Lamberts	NED
2011	Prof. Jens Rehfeld	DEN
2010	Prof. Enrico Solcia	ITA
2009	Prof. Rudolf Arnold	GER
2008	Prof. Jun Soga	JPN
2007	Prof. Lars Grimelius	SWE
2006	Dame Julia M. Polak †	GBR
2005	Prof. Werner Creutzfeldt †	GER
2004	Prof. Michel Mignon	FRA

SCIENTIFIC PROGRAM

ENETS Executive Committee

Massimo Falconi	ITA	Chairman
Martyn Caplin	GBR	Vice-Chairman
Dermot O'Toole	IRL	Chairman-Elect
Bertram Wiedenmann	GER	Treasurer
Aurel Perren	SUI	Scientific Secretary
Rocio Garcia-Carbonero	ESP	Member
Eva Tiensuu Janson	SWE	Member
Reza Kianmanesh	FRA	Member
Marianne Pavel	GER	Member

ENETS Advisory Board

Detlef Bartsch	GER	
Eric Baudin	FRA	
Lisa Bodei	USA	
Ivan Borbath	BEL	(Registry Representative)
Jaume Capdevila	ESP	
Jie Chen	CHN	(Honorary)
Frederico Costa	BRA	
Anne Couvelard	FRA	
Jaroslaw Cwikła	POL	
Philippa Davies	GBR	(NET Nurse Representative)
Wouter W. de Herder	NED	(Advisory Board Chairman)
Gianfranco Delle Fave	ITA	
Barbro Eriksson	SWE	
Jenny Falkerby	SWE	(NET Nurse Representative)
Nicola Fazio	ITA	
Diego Ferone	ITA	
Andrea Frilling	GBR	
Simona Glasberg	ISR	
Vera Gorbunova	RUS	(Honorary)
Ashley Grossman	GBR	
Rodney Hicks	AUS	
Dieter Hörsch	GER	
Robert Jensen	USA	
Gregory Kaltsas	GRE	
Ulrich Knigge	DEN	
Beata Kos-Kudła	POL	
Matthew Kulke	USA	
Dik Kwekkeboom	NED	
Catherine Lombard-Bohas	FRA	
Bruno Niederle	AUT	
Els Nieveen van Dijkum	NED	
Juan O'Connor	ARG	
Kjell Öberg	SWE	
Ulrich-Frank Pape	GER	
Andreas Pascher	GER	
Marc Peeters	BEL	
John Ramage	GBR	

ENETS Advisory Board continued

Eric Raymond	FRA	
Nick Reed	GBR	
Guido Rindi	ITA	
Anja Rinke	GER	
Philippe Ruszniewski	FRA	
Ramon Salazar	ESP	
Aldo Scarpa	ITA	
Jean-Yves Scoazec	FRA	
Halfdan Sørbye	NOR	
Anders Sundin	SWE	
Christos Toumpanakis	GBR	
Juan Valle	GBR	
Chris Verslype	BEL	(Registry Representative)
Marie-Pierre Vullierme	FRA	
Staffan Welin	SWE	
James Yao	USA	

ENETS Centers of Excellence Auditors and Honorary Members

Rudolf Arnold	GER
Günter Klöppel	GER
Guenter J. Krejs	AUT
Eric Krenning	NED
Steven Lamberts	NED
Kjell Öberg	SWE
Matthias Rothmund	GER
Babs Taal	NED

Abstract Reviewing Committee 2017

Lead:

Nicholas Reed	*GBR*

Clinical:		**Basic Science:**	
Philippe Ruszniewski (Chair)	*FRA*	*Anne Couvelard (Chair)*	*FRA*
Jaume Capdevila	*ESP*	*Detlef Bartsch*	*GER*
Wouter W. de Herder	*NED*	*Diego Ferone*	*ITA*
Barbro Eriksson	*SWE*	*Gregory Kaltsas*	*GRE*
Rocio Garcia-Carbonero	*ESP*	*Aurel Perren*	*SUI*
Ulrich Knigge	*DEN*	*Guido Rindi*	*ITA*
Juan O'Connor	*ARG*	*Aldo Scarpa*	*ITA*
Marianne Pavel	*GER*		
John Ramage	*GBR*		
Halfdan Sørbye	*NOR*		
Anders Sundin	*SWE*		

Centers of Excellence (CoE) Young Investigator Grant Reviewing Committee

Dermot O'Toole (Lead)	*IRL*	*Reza Kianmanesh*	*FRA*
Jaume Capdevila	*ESP*	*Matthew Kulke*	*USA*
Rocio Garcia-Carbonero	*ESP*	*Jean-Yves Scoazec*	*FRA*

ENETS CoE Excellence Academy Reviewing Committee

Bertram Wiedenmann (Lead)	*GER*	*Guido Rindi*	*ITA*
Ivan Borbath	*BEL*	*Philippe Ruszniewski*	*FRA*
Martyn Caplin	*GBR*	*Dermot O'Toole*	*IRL*
Wouter W. de Herder	*NED*	*Juan Valle*	*GBR*
Barbro Eriksson	*SWE*		

ENETS CoE Training Fellowship Grant Reviewing Committee

Massimo Falconi (Lead)	*ITA*	*Ashley Grossman*	*GBR*
Martyn Caplin	*GBR*	*Guido Rindi*	*ITA*
Wouter W. de Herder	*NED*		

Travel Grant Reviewing Committee

Philippe Ruszniewski (Lead)	*FRA*	*John Ramage*	*GBR*
Massimo Falconi	*ITA*	*Els Nieveen van Dijkum*	*NED*
Dieter Hörsch	*GER*		

Håkan Ahlman Award Reviewing Committee

Kjell Öberg (Lead)	*SWE*	*Marianne Pavel*	*GER*
Ulrich Knigge	*DEN*	*Aldo Scarpa*	*ITA*
Bruno Niederle	*AUT*	*Massimo Falconi*	*ITA*

Translational Medicine Fellowship Grant Reviewing Committee 2017

Aurel Perren (Lead)	*SUI*	*Juan Valle*	*GBR*
Robert Jensen	*USA*	*Kjell Öberg*	*SWE*

ENETS Grant Recipients

ENETS CoE Excellence Academy Grant Recipients 2017

Elettra Merola	ITA
Mauro Cives	ITA

ENETS CoE Young Investigator Grant Recipient 2017

Alexa Childs	GBR

ENETS CoE Training Fellowship Grant Recipients 2017

Om Jitendra Lakhani	IND
Anna Caterina Milanetto	ITA
Manila Rubino	ITA

ENETS Translational Grant (partially industry - sponsored) Recipients 2017 – 2018

This years recipient will be announced during the awards ceremony.

ENETS Håkan Ahlman Award Recipient 2017

Rajesh Thakker	GBR

ENETS Travel Grant Recipients 2017

Julien Bollard	FRA
David L. Chan	CAN
Luohai Chen	CHN
Jules Derks	NED
Arooj Fatima	PAK
Angela Lamarca	GBR
Faidon Laskaratos	GBR
Yang Lv	CHN
Maria Rinzivillo	ITA
Concetta Sciammarella	ITA
Amit Tirosh	USA
Rachel van Leeuwaarde	NED
Rudolf Werner	GER

SCIENTIFIC PROGRAM

Wednesday, 8 March 2017

Time	Location	Event
08:15 - 09:15	Exhibition area	REGISTRATION & COFFEE
09:15 - 17:15	Room 112	ENETS Postgraduate Course
17:15 - 18:15	Foyer, 1st Floor	WELCOME RECEPTION

Thursday, 9 March 2017

Time	Location	Event
07:30 - 08:30	111	ENETS / NANETS Young Investigator Symposium
07:30 - 08:30	129 & 130	Nurse Workshop
07:30 - 08:30	124-128	Meet the Professor 1-4
08:30 - 08:40	113-116 (Plenary)	Welcome
08:40 - 09:50	113-116 (Plenary)	Session 1: Lessons Learned from Other Cancers
09:50 - 10:20	Exhibition area	COFFEE BREAK
10:20 - 11:20	111	Session 2A: Tumorigenic Mechanisms of NET
10:20 - 11:20	113-116 (Plenary)	Session 2B: Medical Therapies and Goals
11:20 - 12:20	113-116 (Plenary)	Session 3A: Aggressive NEN
11:20 - 12:20	111	Session 3B: Interventional Radiology
12:20 - 12:45	113-116 (Plenary)	Life Achievement Award 2017
12:45 - 14:15	112	Satellite Symposium I Industry-Sponsored
12:45 - 14:15	Exhibition area	LUNCH
14:15 - 15:15	111	Session 4A: Basic Science Abstracts
14:15 - 15:15	113-116 (Plenary)	Session 4B: Clinical Abstracts
15:15 - 16:45	Exhibition area	Poster Session A Poster Walk
16:45 - 17:45	113-116 (Plenary)	Session 5: Multidisciplinary Session: Management of Resectable Liver Metastases
17:45 - 18:45	111	ENETS General Assembly (Members Only)
18:45 - 20:15	112	Satellite Symposium II Industry-Sponsored

Friday, 10 March 2017

07:00 - 08:30	112

Satellite Symposium III
Industry-Sponsored

07:30 - 08:30	129 & 130

Workshop:
Imaging Update

08:30 - 09:30	113-116 (Plenary)

Session 6:
How to Not Do Harm?
Who Should Not Get:

08:30 - 09:45	111

Unmet Needs
in NET Care and Research:
Priorities for Actions
- A Joint Symposium of
INCA and ENETS

09:30 - 09:45	113-116 (Plenary)

Session 7: Surgical Protocols

09:45 - 10:50	Exhibition area

Poster Session B
Poster Walk

10:50 - 11:50	111

Session 8A:
Nurse Symposium

10:50 - 11:50	113-116 (Plenary)

Session 8B:
Response Prediction
and Resistance

11:50 - 12:50	113-116 (Plenary)

Session 9A:
Challenges and Controversies
of Therapy

11:50 - 12:50	111

Session 9B:
Tumor Dynamics in Everyday
Practice. Measuring Tumor
Growth and Aggressiveness:
How Good are We Now?

12:50 - 14:20	112

Satellite Symposium IV
Industry-Sponsored

12:50 - 14:20	Exhibition area

LUNCH

14:20 - 14:45	113-116 (Plenary)

Young Investigator (Presentation
ENETS Grant Winners)

14:45 - 15:10	113-116 (Plenary)

ENETS Grants and Awards
Ceremony 2017

15:10 - 16:10	113-116 (Plenary)

Session 10:
What's New in the Field?

16:10 - 16:20	113-116 (Plenary)

Closing Comment

SCIENTIFIC PROGRAM

25

ASPEN study

A multicentre international study supported by:

ENETS
European Neuroendocrine Tumor Society

A prospective evaluation of the management of Asymptomatic Sporadic nonfunctioning Pancreatic neuroEndocrine Neoplasms ≤ 2 cm

- Researching the management of sporadic asymptomatic nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNENs) ≤ 2 cm

- Seeking patients with asymptomatic NF-PanNENs ≤ 2 cm who undergo surveillance or surgery to compare outcomes and quality of life

- Study requires a new diagnosis of asymptomatic sporadic NF-PanNEN ≤ 2 cm defined by somatostatin receptor imaging or by fine-needle aspiration

- Management will be decided by referring physician

- Yearly high-quality imaging is required during follow-up

- Patients will be recruited for 5 years with a 1 year follow-up at least

- Data will be collected by a web based CRF form

For more information about this study, please contact

Prof Massimo Falconi
Dr Stefano Partelli
aspen.enets@hsr.it
+ 39 02 2643 7697

Dear Colleagues,

Welcome to the 7th Annual ENETS Postgraduate Course. We are sure that this year's course will again prove to be informative and stimulating. The aim is to place emphasis on new advances and how this translates to individual patients including those with complex symptoms and syndromes. ENETS is very happy to have confirmed excellent physicians and researchers representing multiple disciplinary fields as speakers for the Postgraduate Course. We invite all participants to take the opportunity to ask questions and meet the speakers during the breaks. Furthermore, your feedback is always valuable in designing future courses and we look forward to receiving your evaluation forms.

We hope you enjoy the course.

Best wishes,
Martyn Caplin
ENETS Vice-Chairman and Course Organizer

Professor Richard Baum

Richard P. Baum is Chairman and Clinical Director of the THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging at Zentralklinik Bad Berka (ENETS Center of Excellence since 2011). His interest in NET dates back to 1997 when he performed the first peptide receptor radiotherapy (PRRT) in Germany at the University Medical Center of Frankfurt/Main, where he holds a position as Professor of Nuclear Medicine since 1996. In 1989 he was elected as President of the International Research Group in Immunoscintigraphy and Immunotherapy (IRIST). He received numerous awards for his research in radiolabeled monoclonal antibodies and peptides (among others the Mallinckrodt Award of the German Society of Nuclear Medicine in 1989, the Sharabai Memorial Oration Award of the SNM India in 1996, the 2010 F.Y. Khoo Medal by the Singapore Radiological Society and the Agasthiar Award by the SNMI in 2011).

In 2013, he was re-elected IRIST President and also became President of the World Association of Radionuclide and Molecular Therapy (WARMTH). He has published >160 original papers in peer-reviewed journals, edited 3 books and lectured extensively. In 2014, he was honored by the NET Patients Support Group in Germany with the GLORINET Award. The ESMO made him Faculty Member for CUP/Endocrine Tumors in 2017.

Professor Martyn Caplin, BSc Hons, DM FRCP

Martyn Caplin is Professor of Gastroenterology & GI Neuroendocrinology at the Royal Free Hospital and University College London. In addition to being the 2014-2016 Chairman of ENETS, he has served on ENETS Executive Committee since its foundation in 2004. He leads The Royal Free Hospital's "ENETS Centre of Excellence" and leads the "Academic NET Research Unit" across University College London.

He received a Lifetime Achievement Award from the UK & Ireland Neuroendocrine Tumour Society (UKI NETS) in recognition of his clinical leadership and research in the field of NETs. He is a founder and past-chairman of the UK & Ireland Neuroendocrine Tumour Society. 2006-2014 he was a member of the National Cancer Research Institute (NCRI) Upper-G.I. Cancer Committee and he is immediate past Chairman of the NCRI Neuroendocrine Tumour Group.

He has published over one hundred and fifty peer review papers, written multiple book chapters and co-authored two books. He regularly lectures both nationally and internationally. Between 2006-12 he was also the clinical lead for "NHS Evidence" for Gastroenterology and Liver diseases (under the auspices of NICE) chairing annual evidence updates into gastrointestinal and liver disorders.

Professor Jaroslaw B. Cwikła, MD

Dr. Jaroslaw B. Cwikła is Associated Professor at the University of Warmia and Mazury and qualified in Medicine from Warsaw Medical Academy. He trained in Diagnostic Imaging in Olsztyn State Hospital and Medical Centre of Postgraduate Education (CMKP), Warsaw. During this time he subsequently trained in Nuclear Medicine, received diploma of specialization in 1997 and in Radiology in 2001. He has been Consultant in Nuclear Medicine at the CMKP, Warsaw, since 2002. Currently he has a position as Associated Professor in the Department of Radiology, Faculty of Medical Science, University of Warmia and Mazury, Olsztyn, Poland. In 1996 and 2000 he was a research fellow in Royal Free Hospital, London UK, mainly involved in clinical research of general nuclear medicine and NET. He is a pioneer, who introduced radioembolisation (RE) in Poland into clinical practice as a method to treat patients with advanced non-resectable liver tumours. Since 2005, he has been a leader of the Patients Group with Neuroendocrine Tumors in Poland. Dr. Jaroslaw B. Cwikła has published 107 scientific papers, 12 book chapters and 221 abstracts. His scientific work concentrates on diagnosis, therapy and clinical follow-up of NEN.

Dr. Joseph Davar

Dr. Davar's long standing interest is Valvular Heart Disease, Including Carcinoid Heart Disease. Dr. Davar's earlier training was undertaken in Tbilisi and Moscow where he was awarded the esteemed 1984 A. L. Myasnikov Prize of Academy of Medical Sciences of USSR for his book 'Mitral Valve Prolapse'. Completing additional training in The Brompton Hospital and The Royal Free Hospital, he holds the position of Lead Consultant for services including: Valvular Heart Disease, Carcinoid Heart Disease and Imaging (including Stress Echocardiography and CT Coronary Angiography). Dr. Davar regularly lectures both nationally and internationally and published extensively in peer reviewed journals. He leads one of the largest Valvular Heart Disease clinics in UK and the largest Carcinoid Clinic in UK and is an international authority on Carcinoid Heart Disease.

Professor Wouter W. de Herder, MD, PhD

Wouter W. de Herder is Professor of Endocrine Oncology at the Erasmus MC (University Hospital) in Rotterdam, the Netherlands. He is Chairman of a multidisciplinary group for endocrine oncology at the Erasmus MC (tumorwerkgroep endocriene tumoren) and also Head of the ENETS Centre of Excellence for Neuroendocrine Tumors. His major research interests are neuroendocrine and endocrine tumors. He served as a Board Member of the Dutch Society for Endocrinology (NVE) (2009–2014) and served as Chairman (2006-2008) as well as Vice-Chairman of the European Neuroendocrine Tumour Society (ENETS) from 2008-2010.

He is member of the Advisory Boards of ENETS and NANETS and served as local organizing committee (LOC) chair of the 13th European Congress of Endocrinology (ECE2011) in Rotterdam, the Netherlands. He is a member of the editorial boards of PLoS ONE, Neuroendocrinology, Endocrinology, Diabetes & Metabolism Case Reports, Clinical Endocrinology and Endocrine-related Cancer. He is a member of the Publishing and Communications Committee of the ESE and Editor of ESE News.

Professor Rocio Garcia-Carbonero

Rocio Garcia-Carbonero is a medical oncologist with particular expertise in gastrointestinal neoplasias. She coordinates the Gastrointestinal (GI) Tumor Unit at the Hospital Universitario Doce de Octubre and is Associate Professor at the Universidad Complutense in Madrid. She is actively involved in clinical and translational research, and is a member of the Scientific Advisory Group for Oncology (SAG-O) at the European Medicines Agency (EMA) since 2008. Her major areas of research interest are the development of new drugs or therapeutic strategies in the field of GI tumors, particularly NETs, pancreatic and colorectal cancer and development of biomarkers of diagnostic or therapeutic interest in this field.

She has published more than 100 papers in peer-reviewed journals, has been a member of the Executive Committee of the Spanish Society of Medical Oncology (SEOM), and is an active member of various scientific societies (ASCO, ESMO, ENETS) and collaborative groups (EORTC, GETNE, TTD). She is devoted to continued medical education and is now a member of the Oncology PRO working group, ESMO's scientific and educational portal for oncologists. She is a national leader in the field of neuroendocrine tumors, being the president of the Spanish cooperative group in NETs (GETNE) since 2011 and a member of the Executive Committee of the European Neuroendocrine Tumor Society (ENETS) since 2014.

Professor Ashley Grossman, MD, FRCP, FMedSci

Ashley Grossman was awarded an Open Exhibition to St Catharine's College, Cambridge, completed a degree in Psychology/Social Anthropology at the University of London and then entered University College London, where he received a First Class degree in Anatomy. He started in the Dept. of Endocrinology at St Bartholomew's Hospital and medical school, eventually becoming Professor of Neuroendocrinology in 1993.

He moved to OCDEM, Churchill Hospital, in 2011, where he was appointed Professor of Endocrinology at the University of Oxford and in 2012 Fellow of Green-Templeton College. He was awarded MRCP in 1978, FRCP in 1990, MD in 1992 and is a Fellow of the Academy of Medical Sciences in 1999. He has published some 470 peer-reviewed papers and 350 chapters and reviews in the field of hypothalamic and pituitary tumours and endocrine oncology. He was awarded the Clinical Endocrinology Trust prize lecture in 2004 and the ESE Geoffrey Harris Prize in 2014. He has been President of the ENEA, the Society for Endocrinology (2012-2014), Chairman of UKINETS (2010-2012) and was President of the Pituitary Society (2015-2016).

Professor Dieter Hörsch, MD

Prof. Dieter Hörsch heads the department of Internal Medicine/Gastroenterology and Endocrinology at the Zentralklinik Bad Berka since 2006. He is specialized in neuroendocrine tumors, tumors of the gastroenteropancreatic system and interventional endoscopy. In addition, he works as an endocrinologist for out-patients. Prof. Hörsch studied medicine in Mainz, Calgary and San Francisco and completed his clinical training at the Philipps-University Marburg.

He is board certified in internal medicine, gastroenterology and endocrinology. From 1993 to 1995 he worked as a post-doctoral fellow in the group of R. Kahn at Joslin Diabetes Center and at the Harvard Medical School in Boston, USA. Pathophysiology of diabetes and neuroendocrine tumors are his keen scientific interest. Prof. Hörsch published more than 60 articles in peer-reviewed journals, in addition to several book chapters. He has been principal investigator in more than 15 international controlled clinical studies.

Dr. Robert T. Jensen, MD

Dr. Robert T. Jensen is Chief of the Cell Biology Section, Digestive Diseases Branch, Diabetes, Digestive and Kidney Diseases of the National Institutes of Health, USA. He has had a long-standing interest in pancreatic endocrine tumor syndromes, particularly using the Zollinger-Ellison syndrome as a model in which sufficient numbers of patients could be obtained to allow systematic studies.

His studies have involved natural history, diagnosis, systematic analysis of imaging studies, medical control of the gastric acid hypersecretion, role of surgery, molecular-pathologic-clinical correlations to identify prognostic factors and treatment of patients with advanced disease. In addition, he also performed basic science studies related to the cellular basis of action of gastrointestinal hormones including studies of cell signaling, pharmacology and molecular pharmacology. He has published more than 550 papers and more than 90 chapters.

Professor Kjell Öberg, MD, PhD

Kjell Öberg is Professor of Endocrine Oncology at the Medical Faculty of Uppsala University. He was the former Head of the Department of Endocrine Oncology, University Hospital, and he is a specialist in endocrinology and internal medicine. He founded the Dept. of Endocrine Oncology at Uppsala University Hospital and has 40 years of experience in the field of neuroendocrine tumors. In addition to serving as Vice-Chairman of the ENETS Executive Committee he held the position of ENETS Chairman from 2012-2014.

He also headed the first ENETS Summer School, which took place in Uppsala, Sweden in 2014. Dr. Öberg is a member of several national and international scientific societies. He is a member of the NANETS Advisory Board as well as several other national and international research and scientific boards and many scientific journal review boards. Dr Öberg has contributed with more than 500 publications in the field of NETs. He was the chairman for the Centre of Excellence of Endocrine Tumors, Uppsala University Hospital until May 2013. At present time he is Senior Advisor/Senior Professor at the same department.

Professor Guenter J. Krejs, MD

Guenter J. Krejs graduated from the University of Vienna (MD 1969) and received his training in internal medicine and gastroenterology in Zurich, Switzerland (training director André L. Blum). From 1975 to 1986 he was a faculty member (full professor of internal medicine after 1984) at Southwestern Medical School University of Texas Health Science Center in Dallas, Texas (mentor: John S. Fordtran). From 1986 to 2005 he was Chairman of Internal Medicine at the University of Graz, Austria, and Chief of Gastroenterology until 2013. In his research, he extensively studied the effect of VIP (vasoactive intestinal polypeptide) and somatostatin on the intestine. He provided the first description of the somatostatinoma syndrome (NEJM 1979) and he was one of the first to use somatostatin therapeutically in patients with neuroendocrine tumors.

He was President of the Austrian Society of Gastroenterology and Hepatology, the Coordinating Council of the United European Gastroenterology Federation (UEG) and the European Association for Gastroenterology, Endoscopy and Nutrition. In 2016 he received the Lifetime Achievement Award from the UEG.

Dr. Ulrich-Frank Pape, MD

Ulrich-Frank Pape studied medicine at the Free University of Berlin in Germany, between 1989 and 1997, where he later completed his doctorate. During his residency at the Charité-Universitätsmedizin Berlin he also received a postdoctoral research fellowship at the German Cancer Research Center (DKFZ) in Heidelberg.

He is currently Deputy Chair of the Department of Hepatology and Gastroenterology at the Charité-Universitätsmedizin Berlin and specializes in clinical care as well as research of gastrointestinal cancers particularly neuroendocrine neoplasms, nutritional medicine and intestinal failure care. He is a member of the Professional Association of German Internists (BDI), German Society for Digestive and Metabolic Diseases (DGVS), German Working Group of Medical Oncologists (AIO), German Society of Endocrinology (DGE), German Registry Gastrointestinal Neuroendocrine Tumors (NET-Register) and European Neuroendocrine Tumor Society (ENETS) including the ENETS Advisory Board and the ENETS-Registry taskforce.

Professor Andreas Pascher, MD, PhD, MBA, FEBS

Andreas Pascher is Professor of Surgery at the Charité–Universitätsmedizin Berlin, Campus Mitte and Virchow in Berlin, Germany. Prof. Pascher is Deputy Chair of the Department of Surgery and directs the Divisions of HBP-Surgery, NEN-Surgery, CED-Surgery and the multiorgan transplant program (liver, kidney, pancreas, intestine). He is specialized and board-certified in visceral, hepatobiliary, endocrine and transplant surgery. He has been a Fellow of the European Board of Surgeons in transplant surgery since 2010.

In 2010 he also completed his master in health care management at the Berlin School of Economics and Law. He has published over 200 peer-reviewed publications and various book articles on oncologic surgery (incl. NEN), surgery in inflammatory bowel disease, as well as transplant surgery and immunology. He has been Member of the Scientific Advisory Board of the European Neuroendocrine Tumor Society (ENETS), the Intestine Transplant Association, the German Transplant Society, Secretary of the European Liver and Intestinal Transplant Association and elected Member of the Transplant Guideline Commission of the German Medical Chamber.

Professor Marc Peeters, MD

Marc Peeters is Professor of Oncology at the Antwerp University, Belgium. He is Head of the Oncology Department at the Antwerp University Hospital and coordinator of the Multidisciplinary Oncology Center Antwerp. Prof. Peeters is Secretary of the Flemish Society of Gastroenterology. He is vice president of the Belgian Group of Digestive Oncology and member of the Belgian Society of Medical Oncology,

The European Society of Medical Oncology, the American Society for Clinical Oncology and the Gastrointestinal Group of the European Organisation for Research and Treatment of Cancer. His research interests have included the identification of molecular markers and therapy modulation in digestive tumours. He has been involved in many clinical studies on therapeutic agents for gastrointestinal tumours. He published numerous articles in peer reviewed journals and was author of several chapters in oncology books.

SCIENTIFIC PROGRAM

31

Professor Stephen Pereira, BSC, PhD, FRCP, FRCPE

Stephen Pereira is Professor of Gastroenterology and Hepatology at University College London and Consultant at the Royal Free Hospital and University College Hospital, London. The research interests of his group centre are on the pathogenesis and early diagnosis and novel treatments for biliary tract and pancreatic tumours with particular current interests in biomarkers for early pancreatic carcinoma and novel endoscopic techniques. This includes EUS-guided needle based confocal endomicroscopy and radiofrequency ablation of pancreatic tumours.

Professor Aurel Perren, MD

Professor Aurel Perren is Director of the Institute of Pathology at the University of Bern since 2009. He did his pathology training in Zürich with a special focus on endocrine tumors. 2007 to 2009 he was active as Professor of Pathology at the Technische Universität München. His research focus lies on the histopathological, molecular and genetic analysis of familial and sporadic NEN with a special interest in pancreatic NEN.

He was involved in the WHO classification of endocrine tumors 2004 and 2017 and since the first ENETS Frascati meeting in 2005, Aurel Perren is regularly involved in European Neuroendocrine Tumor Society (ENETS) activities where he currently serves as Scientific Secretary of ENETS Executive Committee. His research group in Bern focus on the progression of pancreatic NEN and thyroid carcinomas. The group integrates molecular in-vitro and in-vivo results with clinical and ex-vivo results gained on human tumor tissues.

Dr. Christina Thirlwell, MD, PhD

Doctor Christina Thirlwell is a Senior Lecturer and Consultant in Medical Oncology at the Royal Free Hospital NET Unit and University College London Cancer Institute. She is Chair of the UK and Ireland Neuroendocrine Tumour Society (UKINETS) Research Committee and undergraduate academic lead at UCL Cancer Institute. Dr. Thirlwell completed a PhD in colorectal cancer genetics funded by the Medical Research Council. Whilst completing her Medical Oncology training, she held a National Institute of Health Research Clinical Lecturer post until her appointment as Consultant in 2010.

Dr. Thirlwell leads a research group at the UCL Cancer Institute and has a particular interest in integrated genomic and circulating free DNA analysis of neuroendocrine tumors with the aim of identifying novel therapeutic targets and personalising therapy. To date she has successfully identified sub-groups of NETs with poorer clinical outcomes and has successfully isolated and sequenced DNA from circulating NET cells in the bloodstream (CTCs). She has delivered plenary lectures at UK, European and North American NET meetings and received national and international prizes and awards for research undertaken by her team.

Dr. Christos Toumpanakis MD, PhD, FRCP

Dr. Christos Toumpanakis is a Consultant in Gastroenterology & Neuroendocrine Tumors in the Neuroendocrine Tumor Unit – ENETS Centre of Excellence, at Royal Free Hospital, London, UK, since 2007. He is also an Honorary Senior Lecturer at University College of London and has been awarded as "Top-Teacher of the Year" in 2007, 2009, 2013, 2014 and 2015. He graduated from Medical School-University of Athens, Greece, in 1994, obtained his specialty title in Gastroenterology & Hepatology in 2004 and his PhD from University of Athens in 2007.

He has been involved in the area of NETs since 2000. He has presented in several international conferences and published many original papers and reviews. He is a member of the Advisory Board of the European Neuroendocrine Tumor Society (ENETS), the editor of ENETS CME program, a co-author of ENETS and UKI NET Guidelines, as well as a member of the Advisory Board of UK NET patient foundation. He is leading a NET Clinical Research Group and his main research interests include NET novel biomarkers & molecular imaging and carcinoid heart disease.

Professor Damian Wild, MD

Damian Wild received a M.D. from the University of Basel in Switzerland in 2004 and completed his training in Nuclear Medicine in 2007. He completed his Ph.D. in 2011 at the Institute of Nuclear Medicine, University College London. He was appointed by the University Hospital Basel as Head and Professor of Nuclear Medicine in 2012. His main research interests are the development and clinical translation of novel radiotracers in the field of oncology, including neuroendocrine tumors. He has published more than 40 papers in peer-reviewed journals, including New England Journal of Medicine and Lancet Diabetes and Endocrinology.

SCIENTIFIC PROGRAM

Wednesday, 8 March 2017

The postgraduate program is designed for clinicians and researchers who wish to learn more and are new to NET diagnosis and therapy. Limited seats, prior online registration required.
Time: 09:15 - 17:15

<div style="writing-mode: vertical">SCIENTIFIC PROGRAM</div>

Time	Topic	Room
	ENETS Postgraduate Course *Chairs: Martyn Caplin, GBR / Rocio Garcia-Carbonero, ESP*	112
08:15 - 09:15	REGISTRATION & COFFEE	Exhibition Area
09:15 - 09:30	**Introduction** *Martyn Caplin, GBR*	112
09:30 - 11:10	**Postgraduate Course Part 1** *Chairs: Martyn Caplin GBR / Aurel Perren, SUI*	112
	09:30 - 09:50 **Pathology Overview & New Advances to Aid Therapy** *Aurel Perren, SUI*	
	09:50 - 10:10 **Chromogranin A Is Dead – Long Live the New Biomarkers!** *Christina Thirlwell, GBR*	
	10:10 - 10:20 **Discussion**	
	10:20 - 10:40 **Overview of Medical Management of Midgut NETs and ENETS Guidelines** *Dieter Hörsch, GER*	
	10:40 - 11:00 **Carcinoid Heart Disease** *Joseph Davar, GBR*	
	11:00 - 11:10 **Discussion**	
11:10 - 11:40	COFFEE BREAK	Exhibition Area
11:40 - 13:10	**Postgraduate Course Part 2** *Chairs: Wouter W. de Herder, NED / Rocio Garcia-Carbonero, ESP*	112
	11:40 - 11:48 **Is There Still a Role for Interferon in NETs? - YES** *Kjell Öberg, SWE*	
	11:48 - 11:55 **Is There Still a Role for Interferon in NETs? - NO** *Marc Peeters, BEL*	
	11:55 - 12:00 **Discussion**	
	12:00 - 12:20 **Overview of Medical Management of Pancreatic NETs and ENETS Guidelines** *Rocio Garcia-Carbonero, ESP*	

Wednesday, 8 March 2017

Time	Topic	Room
12:20 - 12:40	**Advances in Endoscopic Ultrasound and Endotherapy for Pancreatic NET** *Stephen Pereira, GBR*	
12:40 - 13:00	**Case Studies: Lessons in Gastrinoma** *Robert Jensen, USA*	
13:00 - 13:10	**Discussion**	
13:10 - 14:10	**LUNCH**	Exhibition Area
14:10 - 15:20	**Postgraduate Course Part 3**	112
	Chairs: Guenter Krejs, AUT / Christos Toumpanakis, GBR	
14:10 - 14:30	**Gastric NETs – Short Case Studies** *Christos Toumpanakis, GBR*	
14:30 - 14:50	**Rectal NETs – Short Case Studies** *Andreas Pascher, GER*	
14:50 - 15:10	**Nutrition for GEP NETs - What Support is Appropriate?** *Ulrich-Frank Pape, GER*	
15:10 - 15:20	**Discussion**	
15:20 - 15:50	**COFFEE BREAK**	Exhibition Area
15:50 - 17:05	**Postgraduate Course Part 4**	112
	Chairs: Martyn Caplin, GBR / Jaroslaw Ćwikła, POL	
15:50 - 16:15	**Paraganaglioma and Phaeochromocytoma Case Studies** *Ashley Grossman, GBR*	
16:15 - 16:35	**Nuclear Medicine Imaging – What Does the Future Hold?** *Damian Wild, SUI*	
16:35 - 16:55	**Nuclear Medicine Therapy – What Does the Future Hold?** *Richard P. Baum, GER*	
16:55 - 17:05	**Discussion**	
17:05 - 17:15	**Summary and Close** *Martyn Caplin, GBR*	112
17:15 - 18:15	**ENETS ANNUAL CONFERENCE WELCOME RECEPTION**	Foyer in front of 112 First floor

SCIENTIFIC PROGRAM

Thursday, 9 March 2017 / POSTER SESSION A /POSTER WALKS*
15:15 - 16:45   Room: Exhibition hall

POSTER WALK SESSION A   BASIC SCIENCE
15:30 - 16:20   Poster walk A1 Basic Science   *(Poster Walk Lead Aurel Perren, SUI)*
15:40 - 16:30   Poster walk A2 Basic Science   *(Poster Walk Lead Guido Rindi, ITA)*
15:50 - 16:40   Poster walk A3 Basic Science   *(Poster Walk Lead Gregory Kaltsas, GRE)*
16:00 - 16:45   Poster walk A4 Basic Science   *(Poster Walk Lead Anne Couvelard, FRA)*

POSTER WALK SESSION A   CLINICAL
15:30 - 16:20   Poster walk A1 Clinical   *(Poster Walk Lead Wouter W. De Herder, NED)*
15:40 - 16:30   Poster walk A2 Clinical   *(Poster Walk Lead Barbro Eriksson, SWE)*
15:50 - 16:40   Poster walk A3 Clinical   *(Poster Walk Lead Juan M. O'Connor, ARG)*
16:00 - 16:45   Poster walk A4 Clinical   *(Poster Walk Lead Nick Reed, GBR)*

Friday, 10 March 2017 / POSTER SESSION B /POSTER WALKS*
09:45 - 10:50   Room: Exhibition hall

POSTER WALK SESSION B   BASIC SCIENCE
09:45 - 10:35   Poster walk B1 Basic Science   *(Poster Walk Lead Aldo Scarpa, ITA)*
09:55 - 10:45   Poster walk B2 Basic Science   *(Poster Walk Lead Detlef Bartsch, GER)*
10:00 - 10:50   Poster walk B3 Basic Science   *(Poster Walk Lead Diego Ferone, ITA)*

POSTER WALK SESSION B   Clinical
09:45 - 10:35   Poster walk B1 Clinical   *(Poster Walk Lead Juan Valle, GBR)*
09:55 - 10:45   Poster walk B2 Clinical   *(Poster Walk Lead Ulrich Knigge, DEN)*
10:00 - 10:50   Poster walk B3 Clinical   *(Poster Walk Lead Wouter W. de Herder, NED)*

Poster Exhibition Overview:

All selected poster walk presentations are listed on next page. Please note that participation in the poster walks are limited to 15 participants. This is offered on first come, first serve basis. A poster session/walk information booth has been set-up in the exhibitor's hall where you can sign up.

Poster Walks

SELECTED BASIC SCIENCE POSTER WALKS FOR POSTER SESSION A AND B

A06	**Christian Fischer**	GER	*Slit2-Robo1 Signaling Activates Ras to Suppress Metastasis and Is Associated with Time-To-Progression in Pancreatic Neuroendocrine Tumors*
A13	**Ana Paula Santos**	POR	*FOXM1 Is Strongly Associated with Cell Proliferation and Is Not Influenced by Metabolic Syndrome in GEP-NETS*
A17	**Joerg Schrader**	GER	*Synergistic Effects of Combining Hsp90 and PI3K Inhibitors with Everolimus in Pancreatic Neuroendocrine Tumors*
B01	**Elham Barazeghi**	SWE	*A Role of TETs and 5-Hydroxymethylcytosine in SI-NETs*
B07	**Meng Ji**	CHI	*Genome-Wide Analysis of lncRNAs in Pancreatic Neuroendocrine Tumors by Microarray*
B10	**Alberto Carmona-Bayonas**	ESP	*High Prevalence of the c.1546delC Germline Mutation in MEN1 Pancreatic Neuroendocrine Tumors*
C01	**Simona Glasberg**	ISR	*The Effect of the Autophagy Inhibitor Chloroquine (CQ), Alone or in Combination with mTOR Inhibitors, on Neuroendocrine Tumor (NET) Growth and Metastatic Spread in Mouse Models*
C04	**Anja Maria Schmitt**	SUI	*Influence of VEGF Splicing on Microvessel Density and Architecture in Pancreatic Neuroendocrine Tumours*
G01	**Ivan Borbath**	BEL	*Prognostic Relevance of Pancreatic Neuroendocrine Tumors Grading on EUS-FNA*
H09	**Angela Lamarca**	GBR	*PD-1, PD-L1 and PD-L2 Expression in Well-Differentiated Small Bowel Gastrointestinal Neuroendocrine Tumours (Wd SB-NETs).*

SELECTED CLINICAL POSTER WALKS FOR POSTER SESSION A AND B

D26	**Panpan Zhang**	CHI	*Multicenter Retrospective Analysis of Clinical and Pathological Features of Gastroesophageal Junction Neuroendocrine Neoplasm(GEJ-NEN)*
E07	**Ashley Clift**	GBR	*Enhanced Prognostication of Grade 1 Small Bowel Neuroendocrine Tumours with Multi-Parametric Clinicopathological Assessment*
E09	**Dalvinder Mandair**	GBR	*Typical Bronchial Neuroendocrine Tumours with Advanced Disease: A Misleading Biology*
E36	**Amit Tirosh**	USA	*Total 68Ga-DOTATATE-Avid Tumor Volume (TV) Predicts Progression-Free Survival (PFS) and Disease-Specific Mortality (DSM) in Patients with Neuroendocrine Tumors (NETs)*
E38	**Linde van Veenendaal**	NED	*Treatment and Survival of 351 Patients Diagnosed with Merkel Cell Carcinoma in 2 Melanoma and Neuroendocrine Tumor Expert-Centers in the Netherlands*
E39	**Wang Wei**	CHI	*Nomogram Individually Predicts the Overall Survival of Patients with Gastroenteropancreatic Neuroendocrine Neoplasms*
J05	**Jules Derks**	NED	*Chemotherapy for Pulmonary Large Cell Neuroendocrine Carcinomas: Does the Regimen Matter?*
K01	**Manuela Albertelli**	ITA	*Safety and Efficacy of High Doses Lanreotide Treatment in Patients with Progressive Neuroendocrine Tumors: Results from a Prospective Phase II Trial*
K16	**Marianne Pavel**	GER	*Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial*
M02	**Leonidas Apostolidis**	GER	*Skeletal-Related Events (SREs) and Use of Antiresorptive Therapy (ART) in Patients with Bone Metastases of Neuroendocrine Neoplasms*
M08	**Marianne Pavel**	GER	*Correlation of Plasma (p) and Urine (u) 5-HIAA Levels in Patients (pts) with Carcinoid Syndrome (CS) - Post-Hoc Analyses from the TELESTAR Study*
N02	**Lisa Bodei**	USA	*Circulating Neuroendocrine Transcripts and Gene Cluster Analysis Predict the Efficacy of PRRT*
N16	**Daan Smit-Duijzentkunst**	NED	*Treatment of Paragangliomas with Lutetium-177-Octreotate Based Peptide Receptor Radionuclide Therapy*
O04	**Jorgelina Coppa**	ITA	*Conditional Survival (CS) Analysis of Liver Resection (LR) for Gastro-Entero-Pancreatic Neuroendocrine Tumor (GEP-NET)*
O20	**Sjoerd Nell**	NED	*Management of MEN1 Related Non-Functioning Pancreatic NETs: A Shifting Paradigm. Results from the Dutch MEN1 Study Group.*
R06	**Myrtille Fouché**	FRA	*Intraoperative Carcinoid Syndrome During Small-Bowel NET Surgery: Description, Prevalence and Risk Factors.*

Thursday, 9 March 2017

Time	Topic	Room

<div style="background:red;color:white;text-align:center">

**ENETS/NANETS Symposium, Nurse Workshop & Meet the Professor
are parallel sessions**

</div>

07:30 - 08:30 **ENETS/NANETS Young Investigator Symposium**   111

Chairs: David Metz, USA / Massimo Falconi, ITA

07:30 - 07:40   **Next-Generation Sequencing (NGS) in Pancreatic Neuroendocrine Tumors (panNETs): Defining Differentiation and Grade Genetically**
Nitya Raj, USA

07:40 - 07:50   **A Prognostic Model for Pulmonary Carcinoid Tumors Based on Large Chromosomal Alterations**
Konstantinos Leventakos, USA

07:50 - 08:00   **GSK3: A Novel Therapeutic Target in NETs?**
Svenja Nölting, GER

08:00 - 08:10   **TSC22D1 Expression and Association with Clinic-Pathological Features in Bronchial Carcinoids**
Giulia Bresciani, ITA

08:10 - 08:20   **Interactions between SSTR Modulation via Lanreotide and Molecular Targeted Therapies in Sequential and Combination Approaches In Vitro**
Sebastian Krug, GER

08:20 - 08:30   **Questions & Answers**

07:30 - 08:30 **Nurse Workshop**   129 & 130

Chair: Kjerstin Skrede Mordal, NOR

Reality in Practice – Gastro-Intestinal Symptoms and Quality of Life in Patients with NET
Elizabeth Quaglia, GBR / Lise Munk Plum, DEN

07:30 - 08:30 **Meet the Professor**   124 - 128

Workshop 1: Pathology: What Modern Pathologists Need to Know for Digestive and pNETs   124
Anne Couvelard, FRA / Günter Klöppel, GER

Workshop 2: Surgical Knowhow "Special Tricks"   125
Alain Sauvanet, FRA / Thomas Steinmüller, GER

Workshop 3: Practical Approaches to "Genetics in NETs"   127
Barbro Eriksson, SWE / Rajesh Thakker, GBR

Workshop 4: Entering Patients in NET Clinical Trials   128
Enrique Grande, ESP / Juan Valle, GBR

Thursday, 9 March 2017

Time	Topic	Room

08:30 - 08:40 **Welcome** 113-116 (Plenary)

Massimo Falconi, ITA

08:40 - 09:50 **Session 1: Lessons Learned from Other Cancers** 113-116 (Plenary)

Chairs: Bertram Wiedenmann, GER / Rocio Garcia-Carbonero, ESP

08:40 - 09:00 **Immune System and Cancer**

Michal Lotem, ISR

09:00 - 09:20 **Tumor Heterogeneity – What Can We Learn from Breast Cancer?**

Jan Dumanski, SWE

09:20 - 09:30 **Immune System and Heterogeneity in Neuroendocrine Tumors**

Matthew Kulke, USA

09:30 - 09:50 **Presidential Abstract: VHL Genotype is Associated with Pancreatic Neuroendocrine Tumors (PNETs) Phenotype in Patients with Von Hippel-Lindau Disease (VHLD)**

Amit Tirosh, USA

09:50 - 10:20 **COFFEE BREAK** Exhibition area

Session 2A and Session 2B are parallel sessions

10:20 - 11:20 **Session 2A: Tumorigenic Mechanisms of NET** 111

Chairs: Aurel Perren, SUI / Eva Tiensuu Janson, SWE

10:20 - 10:35 **MicroRNAs Associated with Small Bowel Neuroendocrine Tumors and their Metastases**

Leandro Castellano, GBR

10:35 - 10:50 **News in Whole Genome Analysis**

Aldo Scarpa, ITA

10:50 - 11:05 **Epidrug - Induced Upregulation of Functional Somatostatin Type 2 Receptors**

Leo Hofland, NED

11:05 - 11:10 **Panel Discussion**

11:10 - 11:20 **Presidential Abstract: Analysis of mTOR, CXCR4 and PD-1 Checkpoint Pathways in Merkel Cell Neuroendocrine Carcinomas: Correlations with Prognosis and Viral Status**

Jonathan Benhamou, FRA

SCIENTIFIC PROGRAM

Thursday, 9 March 2017

Time	Topic	Room

10:20 - 11:20 | **Session 2B: Medical Therapies and Goals** | 113-116 (Plenary)

Chairs: Eric Raymond, FRA / Simona Glasberg, ISR

10:20 - 10:35 | **What's New for Treatment of Refractory Carcinoid Syndrome?**
Ivan Borbath, BEL

10:35 - 10:50 | **When Can We Stop Targeted Therapy in Patients with SD?**
Nicola Fazio, ITA

10:50 - 11:05 | **Whats New in Lung NET?**
Marianne Ellen Pavel, GER

11:05 - 11:10 | **Panel Discussion**

11:10 - 11:20 | **Presidential Abstract: An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967)**
Jian Ming Xu, CHN

Session 3A and Session 3B are parallel sessions

11:20 - 12:20 | **Session 3A: Aggressive NEN** | 113-116 (Plenary)

Chairs: Chris Verslype, BEL / Eric Baudin, FRA

11:20 - 11:40 | **Classification of NEN G3: News and Challenges**
Aurel Perren, SUI

11:40 - 12:20 | **Debate: Any Place for Surgery**

11:40 - 11:55 | **PRO**
Halfdan Sørbye, NOR

11:55 - 12:10 | **CON**
Ulrich Peter Knigge, DEN

12:10 - 12:20 | **Rebuttal Comments**

40

Thursday, 9 March 2017

Time	Topic	Room

11:20 - 12:20 | **Session 3B: Interventional Radiology** | *111*

Chairs: Barbro Eriksson, SWE / Detlef Bartsch, GER

11:20 - 11:35   **Radiology – Radioembolisation, Liver Directed Therapies**
Marnix G.E.H. Lam, NED

11:35 - 11:50   **New Devices and Approaches (RFA, Microwave, Electroporation)**
Alan Sag, TUR

11:50 - 12:05   **Ablative or Loco-Regional Therapy in Patients with Single Growing Lesions in Diffuse Liver Metastases**
Thierry de Baère, FRA

12:05 - 12:10   **Panel Discussion**

12:10 - 12:20   **Presidential Abstract: International Multicenter Retrospective Study on the Efficacy and Toxicity of Radioembolization in Neuroendocrine Tumours with yttrium-90 resin microspheres**
Arthur Braat, NED

12:20 - 12:45 | **Life Achievement Award 2017** | *113-116 (Plenary)*

Chair: Massimo Falconi, ITA

12:20 - 12:30   **Dedication**
Eva Tiensuu Janson, SWE

12:30 - 12:45   **Recipient and Keynote Presentation**
Kjell Öberg, SWE

Satellite Symposium I and Lunch are parallel sessions

12:45 - 14:15 | **Satellite Symposium I, Industry - Sponsored*** | 112

For symposium participants lunch boxes will be available in room 112.

12:45 - 14:15 | **LUNCH** | Exhibition area

*For details, please go to page 66

Thursday, 9 March 2017

Time	Topic	Room

Session 4A and Session 4B are parallel sessions

14:15 - 15:15   **Session 4A: Basic Science Abstracts**   111

Chairs: Guido Rindi, ITA / Staffan Welin, SWE

14:15 - 14:25 **Implication of Neuropilin-2 in the Progression of Small Intestinal Neuroendocrine Tumors: Towards a Promising Therapeutic Target?**
Julien Bollard, FRA

14:25 - 14:35 **Whole-Exome Sequencing (WES) of Samples from Patients (pts) Classified as Exceptional Responders (ER) Versus Poor Responders (PO) to Targeted Therapies in Pancreatic Neuroendocrine Tumours (pNETs)**
Jorge Barriuso, GBR

14:35 - 14:44 **3D Primary Cell Culture: A New Promising Preclinical Model for Pancreatic Neuroendocrine Tumors (pNETs)**
Ilaria Marinoni, SUI

14:44 - 14:54 **Efficacy of Lanreotide (LAN), both Alone and in Combination with Targeted Therapies in a Preclinical Model of Pancreatic Neuroendocrine Tumors (pNETs)**
Oriol Casanovas, ESP

14:54 - 15:03 **PD-L1 is Expressed in a Subset of Pancreatic Neuroendocrine Tumors (pNET)**
Charalampos Saganas, SUI

15:03 - 15:07 **Feasibility and Implication of Routine NGS Analysis in Neuroendocrine Carcinomas**
Ulrich Peter Knigge, DEN

15:07 - 15:11 **Establishment of the First Well-Differentiated in Vivo Human Pancreatic Neuroendocrine Tumor Model**
Joerg Schrader, GER

15:11 - 15:15 **The Expression of IGF Signaling PathwayGenes is Frequently Elevated in Pancreatic Neuroendocrine Tumors, but is Downregulated in Metastases**
Ernst-Jan Speel, NED

SCIENTIFIC PROGRAM

ENETS
European Neuroendocrine Tumor Society

Thursday, 9 March 2017

Time	Topic	Room
14:15 - 15:15	**Session 4B Clinical Abstracts**	113-116 (Plenary)
	Chairs: Beata Kos-Kudła, POL / Nicholas Simon Reed, GBR	

14:15 - 14:25   **NETTER-1 Phase III Trial: Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors**
Jonathan Strosberg, USA

14:25 - 14:35   **Neuroendocrine Neoplasm Trends over 32 Years in Queensland, Australia**
David Wyld, AUS

14:35 - 14:44   **Gastroenteropancreatic High-Grade Neuroendocrine Carcinomas: A SEER Database Analysis of 6291 Cases**
Arvind Dasari, USA

14:44 - 14:54   **Incidence and Characteristics of Ileo-Colonic Neuroendocrine Tumours Identified in the UK Bowel Cancer Screening Programme**
Raj Srirajaskanthan, GBR

14:54 - 15:03   **Adherence to WHO2010 Guideline for Diagnosis of Neuroendocrine Carcinoma and Prognostic Significance**
Wouter Zandee, NED

15:03 - 15:07   **Prognosis of Sporadic Resected Small (≤ 2 cm) Nonfunctional Pancreatic Neuroendocrine Neoplasms: A Multi-Institutional Study**
Sebastien Gaujoux, FRA

15:07 - 15:11   **FDG-PET is Superior to WHO Grading in Predicting Overall Survival of Patients with Neuroendocrine Tumors: A Prospective Study of 172 Patients**
Andreas Kjaer, DEN

15:11 - 15:15   **Pancreatic Neuroendocrine Tumors (pNETs): A Population-Based Analysis of Epidemiology and Outcomes**
Gustavo Westin, USA

Poster Session A and Poster Walks are parallel sessions

Time	Topic	Room
15:15 - 16:45	**Poster Session A**	Exhibition area
	Coffee break is included during the Poster Session	

15:15 - 16:45   **Poster Walks****   Exhibition area

SCIENTIFIC PROGRAM

**Limited access. Poster Walk Presentations are depicted on page 36 and 37

Thursday, 9 March 2017

Time	Topic	Room

16:45 - 17:45   **Session 5: Multidisciplinary Session: Management of Resectable Liver Metastases**   113-116 (Plenary)

Chairs: Anja Rinke, GER / Diego Ferone, ITA

16:45 - 17:00   **Case Presentation**
Christos Toumpanakis, GBR

17:00 - 17:10   **Medical Specialists View**
Simona Glasberg, ISR

17:10 - 17:20   **Radiologists View**
Bernhard Gebauer, GER

17:20 - 17:30   **Surgeons View**
Andrea Frilling, GBR

17:30 - 17:45   **Panel Discussion**

17:45 - 18:45   **ENETS General Assembly (Members Only)**   111

18:45 - 20:15   **Satellite Symposium II, Industry - Sponsored***   112

For symposium participants a snack will be available in room 112.

*For details, please go to page 67

Friday, 10 March 2017

Time	Topic	Room

Satellite Symposium III and Workshop are parallel sessions

07:00 - 08:30 — **Satellite Symposium III, Industry - Sponsored*** — 112

For symposium participants breakfast will be available in room 112.

07:30 - 08:30 — **Workshop: Imaging Update** — 129 & 130

Chair: Marie-Pierre Vullierme, FRA / Reza Kianmanesh, FRA

07:30 - 07:42 **Conventional: DWI, Primovist MRI**
Valérie Vilgrain, FRA

07:42 - 07:54 **Radiological Response Prediction**
Anders Sundin, SWE

07:54 - 08:06 **Impact of Functional Imaging on Management of NET - Where is it Really Needed?**
Rodney Hicks, AUS

08:06 - 08:18 **Endoscopic Imaging (Primary Tumor Identification), EUS for Small Rectal and Gastric NET**
Dermot O'Toole, IRL

08:18 - 08:30 **Open Discussion**

Session 6 / 7 and Joint Symposium are parallel sessions

08:30 - 09:30 — **Session 6: How To Not Do Harm? Who Should Not Get:** — 113-116 (Plenary)

Chairs: Martyn Caplin, GBR / Philippe Ruszniewski, FRA

08:30 - 08:40 **Interventional Radiology**
Eric Baudin, FRA

08:40 - 08:50 **Surgery**
Stefano Partelli, ITA

08:50 - 09:00 **Chemotherapy**
Juan Valle, GBR

09:00 - 09:10 **Targeted Therapy**
Jaume Capdevila, ESP

09:10 - 09:20 **PRRT**
Lisa Bodei, USA

09:20 - 09:30 **Panel Discussion**

SCIENTIFIC PROGRAM

For details, please go to page 68

Friday, 10 March 2017

Time	Topic	Room

08:30 - 09:45   **Unmet Needs in NET Care and Research: Priorities for Actions - A Joint Symposium of INCA and ENETS**   111

Chairs: Massimo Falconi, ITA / Ron Hollander, USA

08:30 - 08:40   **Opening and Introduction**
Massimo Falconi, ITA / Ron Hollander, USA

08:40 - 08:45   **International Neuroendocrine Cancer Alliance (INCA) - The Global Voice for NET Patients**
Teodora Kolarova, BUL

08:45 - 08:55   **Unmet Needs from the Patients' Perspective**
Simone Leyden, AUS

08:55 - 09:05   **Unmet Needs from the Physicians' Perspective**
Bertram Wiedenmann, GER

09:05 - 09:45   **Panel Discussion – How Can We Collaborate to Make Progress on Unmet Needs?**
Moderation: Ron Hollander, USA
Panel: Catherine Bouvier, GBR
Dermot O'Toole, IRL
George Fisher, USA
Rodney Hicks, AUS
Sugandha Dureja, IND
Yoshiyuki Majima, JPN

09:30 - 09:45   **Session 7: ENETS Surgical Protocols**   113-116 (Plenary)

Chairs: Andreas Pascher, GER / Elisabeth Nieveen van Dijkum, NED

09:30 - 09:35   **MEN 1 and the Pancreas**
Bruno Niederle, AUT

09:35 - 09:40   **Intestine: Resection of Primary Intestinal Tumor Versus Conservative Care in Patients with Unrespectable Liver Metastases**
Reza Kianmanesh, FRA

09:40 - 09:45   **Sub-2mc Pancreatic NETS**
Massimo Falconi, ITA

Poster Session B and Poster Walks are parallel sessions

09:45 - 10:50   **Poster Session B**   Exhibition area
Coffee break is included during the Poster Session

09:45 - 10:50   **Poster Walks****   Exhibition area

** Limited access, Poster Walk Presentations are depicted on page 36 and 37

Friday, 10 March 2017

Time	Topic	Room

Session 8A and Session 8B are parallel sessions

10:50 - 11:50 **Session 8A: Nurse Symposium** 111

Chairs: Martyn Caplin, GBR / Philippa Davies, GBR

10:50 - 10:55 **Introduction**
Philippa Davies, GBR

10:55 - 11:10 **UK Survey on the Use of Long-Acting Somatostatin Analogues in NET**
Michael Tadman, GBR

11:10 - 11:25 **Patient Satisfaction Regarding Home Injection Service for Somatostatin Analogues**
Wanda Geilvoet, NED

11:25 - 11:40 **Small Bowel Bacterial Overgrowth in NET Patients**
Tara Whyand, GBR

11:40 - 11:45 **Panel: Questions and Answers**

11:45 - 11:50 **Closing Comments**
Jenny Falkerby, SWE

10:50 - 11:50 **Session 8B: Response Prediction and Resistance** 113-116 (Plenary)

Chairs: Ashley Grossman, GBR / Kjell Öberg, SWE

10:50 - 11:00 **Basic Principals**
Oriol Casanovas, ESP

11:00 - 11:10 **Molecular Pathology**
Jean-Yves Scoazec, FRA

11:10 - 11:20 **Metabolic Symbiosis, A Resistance Mechanism**
Elizabeth Allen, BEL

11:20 - 11:30 **Resistance in Anti-Angiogenic Therapy**
Ruben Bill, SUI

11:30 - 11:40 **Functional Imaging**
Marion Hendriks de Jong, NED

11:40 - 11:45 **Panel Discussion**

11:45 - 11:50 **Presidential Abstract: Tumour Size is not a Reliable Criterion for Resection of Patients with Non-Secreting Pancreatic Neuroendocrine Tumours: Results of an International, Multi-Centre, Operative Cohort**
Logan Mills, GBR

Friday, 10 March 2017

Time	Topic	Room

Session 9A and Session 9B are parallel sessions

11:50 - 12:50 — **Session 9A: Challenges and Controversies of Therapy** — 113-116 (Plenary)

Chairs: Halfdan Sørbye, NOR / Vera Gorbunova, RUS

11:50 - 12:08 — **Over or Under Treating Appendiceal NET? Current Evidence in this Field**
Gregory Kaltsas, GRE

12:08 - 12:25 — **Role of Minimal Invasive Procedures Versus Open Surgical Resection Digestive Tract and Pancreas**
Detlef Bartsch, GER

12:25 - 12:39 — **Sequencing Therapy in Pancreatic NET**
Jonathan Strosberg, USA

12:39 - 12:42 — **Panel Discussion**

12:42 - 12:50 — **Presidential Abstract: Comparison of Long Terms Outcomes after Resection of Hepatic and/or Peritoneal Metastasis from Neuroendocrine Tumors**
Léonor Benhaim, FRA

11:50 - 12:50 — **Session 9B: Tumor Dynamics in Everyday Practice. Measuring Tumor Growth and Aggressiveness: How Good are We Now?** — 111

Chairs: Frederico Costa, BRA / John Ramage, GBR

11:50 - 12:10 — **Biology/Pathology**
Guido Rindi, ITA

12:10 - 12:20 — **Radiology**
Clarisse Dromain, SUI

12:20 - 12:30 — **Clinician**
Ulrich-Frank Pape, GER

12:30 - 12:40 — **Functional Imaging: Pro/Con**
Andreas Kjaer, DEN

12:40 - 12:50 — **Panel Discussion**

Satellite Symposium IV and Lunch are parallel sessions

12:50 - 14:20 — **Satellite Symposium IV, Industry - Sponsored*** — 112

For Symposium participants lunch boxes will be available in room 112.

12:50 - 14:20 — **LUNCH** — Exhibition area

For details, please go to page 69

Scientific Program

Friday, 10 March 2017

Time	Topic	Room

14:20 - 14:45 — **Young Investigator (Presentation ENETS Grant Winners)** — 113-116 (Plenary)

Chair: Massimo Falconi, ITA

14:20 - 14:24 **CoE Excellence Academy Fellowship 2017 - 1**
Elettra Merola, ITA

14:24 - 14:28 **CoE Excellence Academy Fellowship 2017 - 2**
Mauro Cives, ITA

14:28 - 14:32 **CoE Excellence Academy Fellowship 2016**
Henning Jann, GER

14:32 - 14:37 **CoE Young Investigator Grant 2016**
Joakim Crona, SWE

14:37 - 14:41 **CoE Young Investigator Grant 2015**
Jerome Cros, FRA

14:41 - 14:45 **ENETS Translational Medicine Fellowship 2015 – 2016 (partially industry sponsored)**
Su-Chen Li, SWE

14:45 - 15:10 — **ENETS Grants and Awards Ceremony 2017** — 113-116 (Plenary)

Chair: Massimo Falconi, ITA

15:10 - 16:10 — **Session 10: What's New in the Field?** — 113-116 (Plenary)

Chairs: Juan Manuel O'Connor, ARG / Ramon Salazar, ESP

15:10 - 15:30 **What's New in NET Understanding?**
James Yao, USA

15:30 - 15:50 **What's New in Biology / Pathology?**
Marco Volante, ITA

15:50 - 16:10 **Overview of Best Clinical and Basic Science Abstracts**
Robert Jensen, USA

16:10 - 16:20 — **Closing Comment** — 113-116 (Plenary)

Massimo Falconi, ITA

The titels of all approved abstracts include first authors and are listed here:

A. BASIC SCIENCE - SIGNALING PATHWAYS, RECEPTORS, BIOMARKERS

PA **(A1)*** **Benhamou J et al.** *Analysis of mTOR, CXCR4 and PD-1 Checkpoint Pathways in Merkel Cell Neuroendocrine Carcinomas: Correlations with Prognosis and Viral Status*

OA **(A2)** **Bollard J et al.** *Implication of Neuropilin-2 in the Progression of Small Intestinal Neuroendocrine Tumors: Towards a Promising Therapeutic Target?*

(A3) **Cella CA et al.** *Angiogenic Circulating Biomarkers in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus*

(A4) **Diaz Perez A et al.** *Expression of Truncated Functional Subtype 5 Somatostatin Receptor Variant (sst5TMD4) in GEP-NETs and Association with Relevant Pathways Involved in NET Tumorigenesis*

E/N **(A5)** **Falletta S et al.** *TSC22D1 Expression and Association with Clinic-Pathological Features in Bronchial Carcinoids*

PW **(A6)** **Fischer C et al.** *Slit2-Robo1 Signaling Activates Ras to Suppress Metastasis and Is Associated with Time-To-Progression in Pancreatic Neuroendocrine Tumors*

OA **(A7)** **Henfling M et al.** *The Expression of IGF Signaling Pathway Genes Is Frequently Elevated in Pancreatic Neuroendocrine Tumors, but Is Down-regulated in Metastases*

(A8) **Hoffmann J et al.** *The Role of MAPK-Signalling in Pancreatic Neuroendocrine Cancer*

(A9) **Ji Y et al.** *Potential Therapeutic Targets for Gastric Poorly Differentiated Neuroendocrine Carcinoma*

E/N **(A10)** **Krug S et al.** *Interactions between SSTR Modulation via Lanreotide and Molecular Targeted Therapies in Sequential and Combination Approaches in Vitro*

(A11) **Lee L et al.** *Evaluation of Somatostatin and Dopamine Receptor Subtype Expression in Pancreatic Neuroendocrine Neoplasms*

(A12) **Lelek S et al.** *Antiproliferative Effects of Lanreotide in Neuroendocrine Tumors*

PW **(A13)** **Pereira R et al.** *FOXM1 Is Strongly Associated with Cell Proliferation and Is not Influenced by Metabolic Syndrome in GEP-NETS*

(A14) **Romano D et al.** *A Kinomic Approach to Identify Signaling Proteins Involved in Drug Resistance in GastroEnteroPancreatic Neuroendocrine Tumors*

OA **(A15)** **Saganas C et al.** *PD-L1 Is Expressed in a Subset of Pancreatic Neuroendocrine Tumors (pNET)*

(A16) **Sciammarella C et al.** *Cytokines as Predictive Factors of Response to Somatostatin Analogues in Patients with Neuroendocrine Tumour*

PW **(A17)** **Weissmann V et al.** *Synergistic Effects of Combining Hsp90 and PI3K Inhibitors with Everolimus in Pancreatic Neuroendocrine Tumors*

B. BASIC SCIENCE - GENETICS, EPIGENETICS, MIRNAS, OMICS

PW **(B1)** **Barazeghi E et al.** *A Role of TETs and 5-Hydroxymethylcytosine in SI-NETs*

OA **(B2)** **Barriuso J et al.** *Whole-Exome Sequencing (WES) of Samples from Patients (pts) Classified as Exceptional Responders (ER) vs Poor Responders (PO) to Targeted Therapies in Pancreatic Neuroendocrine Tumours (pNETs)*

(B3) **Dou D et al.** *Hsa-microRNA-202-3p Up-regulated in Type 1 Gastric Neuroendocrine Neoplasms*

(B4) **Fatima A et al.** *Development of Neuroendocrine Tumors in Patients with a Family History of NET or Any Other Cancer*

(B5) **Frampton AE et al.** *MicroRNAs Associated with Small Bowel Neuroendocrine Tumours and Their Metastases*

(B6) **Ji M et al.** *Genome-Wide Analysis of Long Non-Coding RNAs in Pancreatic Neuroendocrine Tumors by Microarray*

PW **(B7)** **Ji M et al.** *Genome-Wide Analysis of lncRNAs in Pancreatic Neuroendocrine Tumors by Microarray*

(B8) **Jin K et al.** *Nucleolin (NCL) Regulates Aerobic Glycolysis in Pancreatic Neuroendocrine Tumor (p-NET) BON-1 Cells*

OA **(B9)** **Knigge UP et al.** *Feasibility and Implication of Routine NGS Analysis in Neuroendocrine Carcinomas*

PW **(B10)** **Marín Zafra G et al.** *High Prevalence of the c.1546delC Germline Mutation in MEN1 Pancreatic Neuroendocrine Tumors*

(B11) **Xie Y et al.** *Genetic Features and Immunoprofile of Sporadic Well-Differentiated Neuroendocrine Tumors of Gastric*

*The numbers given to the abstracts e.g. A1, B1 etc. are also the same numbers for the posters displayed in the exhibition hall.

SCIENTIFIC PROGRAM

C. BASIC SCIENCE - IN VITRO MODELS, TUMOR GROWTH, CTCS

PW *(C1)* **Avniel-Polak S et al.** *The Effect of the Autophagy Inhibitor Chloroquine (CQ), Alone or in Combination with mTOR Inhibitors, on Neuroendocrine Tumor (NET) Growth and Metastatic Spread in Mouse Models*

(C2) **Herrera-Martínez AD et al.** *Potential Anti-Tumor Activity of Biguanides and Statins in Neuroendocrine Tumor Cells*

OA *(C3)* **Marinoni I et al.** *3D Primary Cell Culture: A New Promising Preclinical Model for Pancreatic Neuro-Endocrine Tumors (pNETs)*

PW *(C4)* **Marinoni I et al.** *Influence of VEGF Splicing on Microvessel Density and Architecture in Pancreatic Neuroendocrine Tumours*

(C5) **Meyer T et al.** *CALM-NET, A Multicentre, Exploratory Study to Assess the Clinical Value of Circulating Tumour Cells (CTCs) Enumeration in Patients (Pts) with Functioning Midgut NETs Receiving Lanreotide Autogel (LAN)*

(C6) **Quaresmini D et al.** *CXCR4 Inhibition by Ulocuplumab Prevents EMT of pNET Cells in Vitro*

OA *(C7)* **Schrader J et al.** *Establishment of the First Well-Differentiated In Vivo Human Pancreatic Neuroendocrine Tumor Model*

D. EPIDEMIOLOGY/NATURAL HISTORY/PROGNOSIS - REGISTRIES, NATIONWIDE AND REGIONAL SURVEYS

OA *(D1)* **Basuroy R et al.** *Incidence and Characteristics of Ileo-colonic Neuroendocrine Tumours Identified in the UK Bowel Cancer Screening Programme*

(D2) **Begum N et al.** *Quality of Life, Anxiety and Depression in Patients with NEN after Surgery*

(D3) **Chen L et al.** *Multicenter Analysis of the Clinicopathological Characteristics and Prognosis of Colonic Neuroendocrine Neoplasms*

(D4) **Chen L et al.** *The Clinicopathological Characteristics of Small Intestinal Neuroendocrine Neoplasms: A Multicenter Retrospective Study from China*

(D5) **Chen L et al.** *The Clinicopathological Characteristics and Prognosis of Rectal Neuroendocrine Neoplasms: A Multicenter Retrospective Study from China*

OA *(D6)* **Dasari A et al.** *Gastroenteropancreatic High-Grade Neuroendocrine Carcinomas: A SEER Database Analysis of 6291 Cases*

(D7) **Fica S et al.** *Report on the Clinicopathological Characteristics of 548 Romanian Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs*

(D8) **Genc C et al.** *Management of Neuroendocrine Tumors in the Netherlands*

(D9) **Guardeño R et al.** *Ecological Study to Assess the Management of Gastroenteropancreatic Neuroendocrine Tumors in Spain*

(D10) **Jimenez Fonseca P et al.** *Neuroendocrine Tumors Committee of Reference Hospital: Evaluation of Health Care and Research Indicators*

(D11) **Khan M et al.** *International Patient Survey of Physical, Emotional and Informational Challenges when Living with NETs: Understanding the Unmet Needs*

(D12) **Komarova L et al.** *Characteristics of Bronchopulmonary Carcinoids in Cancer Centre Database in Moscow*

(D13) **Lesén E et al.** *Treatment Patterns and Survival Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours in Sweden – A Population-Based Register-Linkage and Medical Chart Review Study*

(D14) **Masui T et al.** *Establishment of Japan NeuroEndocrine Tumor Society and Its Registration System*

(D15) **Ovcinnikova O et al.** *Epidemiology of Carcinoid Heart Disease (CHD) in Patients (pts) with Carcinoid Syndrome (CS): A Systematic Literature Review*

(D16) **Ovcinnikova O et al.** *What Do We Know about Carcinoid Heart Disease? A Systematic Literature Review*

(D17) **Qiu XD et al.** *The Epidemiological Study of Neuroendocrine Neoplasms: A Single-Center Retrospective Analysis of 710 Patients in China*

(D18) **Ramage J et al.** *National Cancer Intelligence Network Data for NET in England- Accuracy by Comparison to a Large Clinical Database*

(D19) **Rosiek V et al.** *Neuroendocrine Neoplasm Registry: Single-Centre Experience and Outcomes*

SCIENTIFIC PROGRAM

(D20) *Tang J et al.* Comparative Analysis of Computed Tomography Features in Pancreatic Neuroendocrine Neoplasms (pNENs) with Different Pathological Grade (G1 and G2)

(D21) *Tang J et al.* Comparative Analysis of CT Features in pNENs with Different Pathological Grade (G1 and G2)

(D22) *Toriyama K et al.* Prospective Observational Study 1 on the Prognosis of Patients with Unresectable Advanced Gastrointestinal and Pancreatic Neuroendocrine Tumors (PROP-UP 1 Study) in Japan

(D23) *Vladova P et al.* Changes in the Frequency and Epidemiology of the Gastroenteropancreatic Neuroendocrine Tumors, Diagnosed in the University Hospital of Pleven, Bulgaria from the Period 2010 to November 2016

OA (D24) *Westin G et al.* Pancreatic Neuroendocrine Tumors (pNETs): A Population-Based Analysis of Epidemiology and Outcomes

OA (D25) *Wyld DK et al.* Neuroendocrine Neoplasm Trends over 32 Years in Queensland, Australia

PW (D26) *Zhang P et al.* Multicenter Retrospective Analysis of Clinical and Pathological Features of Gastroesophageal Junction Neuroendocrine Neoplasm(GEJ-NEN)

E. EPIDEMIOLOGY/NATURAL HISTORY/PROGNOSIS - PROGNOSIS

(E1) *Alabraba E et al.* Prognostic Factors That Mandate Long Term Follow up Following Surgery for Appendiceal Neuroendocrine Tumours (aNETs)

(E2) *Alexandraki K et al.* Dedifferentiation of Metastatic Pancreatic Neuroendocrine Neoplasms

(E3) *Apostolidis L et al.* Prognosis and Treatment Outcomes of Patients with Mixed Adenoneuroendocrine Carcinoma (MANEC) – A Single Cancer Center Experience

(E4) *Cavalcoli F et al.* High Rate of Second Neoplasms in Patients with a Bronchial Neuroendocrine Tumor

(E5) *Cheng F et al.* Patterns of Treatment and Prognosis of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs): Results from Multicenter Database of China

(E6) *Chin JL et al.* Natural History of Type 1 Gastric Carcinoid (gNENs) and Risk of Adenoma/Adenocarcinoma in Endoscopic Surveillance Programme

PW (E7) *Clift A et al.* Enhanced Prognostication of Grade 1 Small Bowel Neuroendocrine Tumours with Multi-Parametric Clinicopathological Assessment

(E8) *Dam G et al.* Prevalence of Carcinoid Heart Disease in Patients with Disseminated Small Intestinal NET

PW (E9) *Diamantopoulos LN et al.* Typical Bronchial Neuroendocrine Tumours with Advanced Disease: A Misleading Biology

(E10) *Elgendy K et al.* Improving Outcomes for Patients with Resectable Small Bowel NET Tumours; Five Year Experience from a Tertiary Centre

(E11) *Frizziero M et al.* Mixed Adeno-Neuroendocrine Carcinoma (MANEC) of the Gastrointestinal (GI Tract: Experience of a European Neuroendocrine Tumour Society (ENETS) Centre of Excellence

(E12) *Genc C et al.* Meta-Analysis of Recurrence after Curative Surgery of Pancreatic Neuroendocrine Tumors

(E13) *Genc C et al.* A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Non-Functional Pancreatic Neuroendocrine Tumors

(E14) *Gengzhou W et al.* The Clinical Pathological Characteristics and Prognostic Factors of Rectal Neuroendocrine Tumors - A Retrospective Analysis Based on Multi Center Data

(E15) *Goh B et al.* Validation and Comparison between Current Prognostication Systems for Pancreatic Neuroendocrine Neoplasms: Single Institution Experience with 176 Patients

(E16) *Grigorescu RR et al.* Clinical Characteristics and Treatment Outcome of Advanced G3 Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)- A Retrospective Analysis

(E17) *Haig J et al.* Carcinoid Heart Disease (CHD): Prognostic Value of 5-HIAA and Impact on Survival – A Systematic Literature Review

(E18) *Jian-Wei X et al.* Different Long-Term Oncologic Outcomes after Radical Surgical Resection for Neuroendocrine Carcinoma and Adenocarcinomas of Stomach - A Propensity Score Case-Match Approach

(E19) *Jiaqi H et al.* Clinicopathological Features and Prognosis of 35 Patients with Gastric Neuroendocrine Carcinomas: A Single-Center Experience

(E20) *Jimenez Fonseca P et al.* Long-Term Outcomes and Prognostic Factors of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs): An Update of a Large National Registry (RGETNE)

(E21) *Kidd M et al.* A Gene Expression-Based Nomogram Predicts Progression Free Survival in Small Bowel NETs

Legend: Selected for: Oral Abstract **OA** */ Presidential Abstract* **PA** */ Poster Walks* **PW** */ ENETS/NANETS Young Investigator Symposium* **E/N**

(E22) **Koffas A et al.** *Predictive Factors for Survival in Patients with Pancreatic Neuroendocrine Tumours*

(E23) **Kolasińska-Ćwikła A et al.** *Clinical Nomogram Development and Predictive Utility for Appendiceal and Colorectal NETs*

(E24) **Kolasińska-Ćwikła A et al.** *Neuroendocrine Carcinomas Pancreatic Origin, Polish Experience*

(E25) **Laskaratos F et al.** *Predictors of Survival in Patients with Small Intestinal Neuroendocrine Tumours (SINETs) Associated with Mesenteric Desmoplasia*

(E26) **Long-Long C et al.** *The Preoperative Blood Lymphocyte-To-Monocyte Ratio Acts As a Superior Prognostic Factor and Predicts Tumor Metastasis in Gastric Neuroendocrine Neoplasms after Surgery*

(E27) **Long-Long C et al.** *Trends of Incidence and Survivals for Gastric Neuroendocrine Neoplasms: An Analysis of 3523 Patients in the SEER Database*

(E28) **Massironi S et al.** *A Role for Vitamin D in the Gastro-Entero-Pancreatic Neuroendocrine Neoplasms Outcome: Report on a Series from a Single Institute*

(E29) **Massironi S et al.** *Heterogeneity of Duodenal Neuroendocrine Tumors: A Multi-Centre Experience in Italy*

(E30) **Massironi S et al.** *Effects of Low-Doses Aspirin on Clinical Outcome and Disease Progression in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors: Results of a Multicentric Retrospective Study*

(E31) **Panzuto F et al.** *Type 3 Gastric Neuroendocrine Neoplasms: Relationship Between Tumor Size, Ki67 and Clinical Outcome*

(E32) **Pusceddu S et al.** *External Validation of Prognostic Classification Score for Predicting Overall Survival (OS) of Patients (pts) with Advanced Well Differentiated Neuroendocrine Tumour (WDNET). Neuroendocrine European Prognostic Score (NEP Score Working Group)*

(E33) **Rinzivillo M et al.** *Heterogeneity of Type 1 Gastric Neuroendocrine Neoplasms*

(E34) **Tan HY et al.** *Subtype Classification and Clinicopathological Features of Gastric Neuroendocrine Neoplasms: An Analysis of 241 Cases*

PA **(E35)** **Tirosh A et al.** *VHL Genotype Is Associated with Pancreatic Neuroendocrine Tumors (PNETs) Phenotype in Patients with Von Hippel-Lindau Disease (VHLD)*

PW **(E36)** **Tirosh A et al.** *Total 68Ga-DOTATATE-Avid Tumor Volume (TV) Predicts Progression-Free Survival (PFS) and Disease-Specific Mortality (DSM) in Patients with Neuroendocrine Tumors (NETs)*

(E37) **Tsoukalas N et al.** *Prevalence of Pancreatic Neuroendocrine Neoplasms with Serotonin Secretion*

PW **(E38)** **van Veenendaal LM et al.** *Treatment and Survival of 351 Patients Diagnosed with Merkel Cell Carcinoma in 2 Melanoma and Neuroendocrine Tumor Expert-Centers in the Netherlands*

PW **(E39)** **Wei W et al.** *Nomogram Individually Predicts the Overall Survival of Patients with Gastroenteropancreatic Neuroendocrine Neoplasms*

F. EPIDEMIOLOGY/NATURAL HISTORY/PROGNOSIS - DESCRIPTIVE EPIDEMIOLOGY

(F1) **Alexandraki K et al.** *Multiple Endocrine Neoplasia Type 1 (MEN1): The Experience of a Referral Center in Greece*

(F2) **Baciu I et al.** *Evolution of Gastroenteropancreatic Neuroendocrine Tumors – Experience of a Romanian Endocrine Clinic*

(F3) **Boutzios G et al.** *The Prevalence of Intestinal Metaplasia in Patients with Gastric Neuroendocrine Neoplasms Type 1*

(F4) **Cavalcoli FA et al.** *Clinical Characterization of Patients with Neuroendocrine Neoplasm of the Appendix in Ireland and in Italy: A Retrospective Study from Two Tertiary Institutions*

(F5) **Cortegoso Valdivia P et al.** *Pancreatic Involvement in VHL Disease: The Turin Experience*

(F6) **Demetriou G et al.** *Clinical Outcomes in Small Neuroendocrine Tumours Treated with Intestinal Surgery in Tertiary Centre*

(F7) **Fatima A et al.** *Investigating the Increasing Incidence of Neuroendocrine Tumors in Pakistan As a Result of Increased Awareness*

(F8) **Jinhu F et al.** *A Multicenter 10-Year Clinical Epidemiological Study of Rectal Neuroendocrine Tumors in China*

(F9) **Koffas A et al.** *Epidemiological Factors at Diagnosis in a Large Cohort of Patients with Pancreatic Neuroendocrine Tumours*

(F10) **Lal DPCK et al.** *Clinical Significance of Incidental Detection of Appendicular Neuroendocrine Tumours in Sri Lanka*

Legend: Selected for: Oral Abstract OA/ Presidential Abstract PA/ Poster Walks PW/ ENETS/NANETS Young Investigator Symposium E/N

53

SCIENTIFIC PROGRAM

(F11) *Lombard-Bohas C et al.* OPALINE Study: Observational Study in a Real-World Setting of the Systemic Treatment of Progressive Unresectable or Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)

(F12) *Lybaert W et al.* Prospective Study on the Impact of a Multi-Institutional NET-Specific Multidisciplinary Tumor Board on Individual Treatment Plans

(F13) *Lybaert W et al.* Launching "NETwerk": Diagnosis and Treatment of Neuroendocrine Tumors within a Multi-Institutional Collaboration in the Region of Antwerp-Waasland in Belgium

(F14) *O'Connor JM et al.* Liver Metastatic Disease (LMD) in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET): Incidence, Treatment and Survival in a Multicenter Study in Argentina. Preliminary Report. ARGENTUM GROUP

(F15) *Peiró I et al.* Observational Study of Small Pancreatic Neuroendocrine Incidentalomas: A Tertiary Referral Center Experience

(F16) *Peralta Ferreira M et al.* NET – Incidental Findings: Small, Silent and Innocent?

(F17) *Santos AP et al.* Abdominal Obesity, Fasting Glucose and Metabolic Syndrome Are Risk Factors for Well Differentiated Digestive Neuroendocrine Tumors

(F18) *Sumbul AT et al.* Clinicohistopathological Features and Treatment Outcomes of Neuroendocrine Tumors; A Single Center Experience

(F19) *Tai WD et al.* Clinicopathologic Characteristics and Survival of Patients with Gastro-Enteropancreatic Neuroendocrine Neoplasm (GEP-NEN) in a Multi-Ethnic Asian Institution

(F20) *Tsang E et al.* Sequence of Therapy and Survival among Advanced Pancreatic Neuroendocrine Tumors (pNETs)

(F21) *Venezia L et al.* Concomitant Intraductal Papillary Mucinous Neoplasms and Neuroendocrine Tumors of the Pancreas: More Than Just a Coincidence?

(F22) *Whyand T et al.* Assessment of Small Intestinal Bacterial Overgrowth (SIBO) in NET Patients

G. PATHOLOGY, GRADING, STAGING

PW **(G1)** *Boutsen L et al.* Prognostic Relevance of Pancreatic Neuroendocrine Tumors Grading on EUS-FNA

(G2) *Chen L et al.* Two Separate Modified ENETS Staging Classifications Are Needed for Duodenal and Jejunoileal Neuroendocrine Neoplasms

(G3) *Chiloiro S et al.* Pancreatic Neuroendocrine Tumors in MEN1 Disease: A Monocentric Longitudinal and Prognostic Study

(G4) *Fatima A et al.* Exploring the Pathological and Clinical Characteristics of Neuroendocrine Tumors Located in Pancreas

(G5) *Gao H et al.* Is Ki67 Index in Biopsy Tissue Truly Reflect Grading of Pancreatic Neuroendocrine Neoplasm?

(G6) *Geng H et al.* Pathological Features of High Proliferative Activity Neuroendocrine Tumor

(G7) *Gurevich LE et al.* The Prognostic Value of the Expression of Cytokeratin 7 and 19 in Lungs and Pancreas Neuroendocrine Tumors

(G8) *Holmager P et al.* Increase of the Ki67 Proliferation Index over Time in Patients with Neuroendocrine Neoplasms

(G9) *Ji Y et al.* Sporadic Gastric Neuroendocrine Neoplasm Include Two Different Subtype-Two Histologically and Clinicopathologically Distinct Entity

(G10) *Kasajima A et al.* Prognosis and Incidence in Pancreatic and Gastrointestinal Neuroendocrine Neoplasms with Emphasis on "NET G3": An Analysis of 198 Cases from Japan

(G11) *Kasajima A et al.* Classification of Lung Neuroendocrine Neoplasms (Lung-NENs) According to WHO 2010 for Gastroenteropancreatic NENs (GEP-NENs) Has Prognostic Relevance and Includes Lung-NETs G3

(G12) *Milione M et al.* Immune-Related Factors Analysis Enhances the Stratification of GEP-NENs Patients Into Distinct Prognostic Subsets

(G13) *Hentic O et al.* Well-Differentiated G1/G2 Pancreatic NETs Can Evolve Towards G3 Tumors

(G14) *Paklina O et al.* Infrastructural Alterations in Insulinoma

(G15) *Sánchez Cánovas M et al.* Histological Differentiation Provides Useful, Additive and Independent Prognostic Information to Proliferation Index in G2 and G3 Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)

(G16) **Shang L et al.** *High-Grade Gastroenteropancreatic Neuroendocrine Tumors Compare to Neuroendocrine Carcinomas in 276 Patients*

(G17) **Shi H et al.** *A Better Ki-67 Index Cutoff to Redefine Low Grade NET and High Grade NEC in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms*

(G18) **Westin G et al.** *Staging Classification Comparison of Resected Pancreatic Neuroendocrine Tumors (pNETs) Utilizing the National Cancer Database (NCDB)*

(G19) **Yinying W et al.** *The Positive Expression of PD-L1/PD-1 in Gastroenteropancreatic Neuroendocrine Neoplasias Correlates with Prognosis*

OA **(G20)** **Zandee W et al.** *Adherence to WHO2010 Guideline for Diagnosis of Neuroendocrine Carcinoma and Prognostic Significance*

H. BIOMARKERS

(H1) **Basuroy R et al.** *Biomarkers for Carcinoid Heart Disease*

(H2) **Chaudhry R et al.** *Evaluation of Faecal Elastase 1 in Symptomatic Patients with Neuroendocrine Tumours*

(H3) **Chen L et al.** *The Clinical Significance of Elevated Serum Procalcitonin in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms*

(H4) **Hadoux J et al.** *Mismatch Repair (MMR) Protein Expression is Uncommon in Poorly Differentiated Neuroendocrine Carcinoma*

(H5) **Hayes AR et al.** *Peripheral Blood Biomarkers of Systemic Inflammation May Be Prognostic in Metastatic Gastroenteropancreatic Neuroendocrine Tumour (GEPNET) Patients Following 177Lu-DOTATATE (LuTate)*

(H6) **Kjellman M et al.** *Plasma Protein Fingerprinting for the Diagnosis of Small Intestinal Neuroendocrine Tumors (siNETs)*

(H7) **Kossai M et al.** *PD-L1 Expression and Quantitative Assessment of Tumor-Infiltrating T Cell Subsets in Carcinoid Tumors and Large Cell Neuroendocrine Carcinomas of the Lung*

(H8) **Kruljac I et al.** *A Nomogram Consisted of Routine Biochemical Tests May Increase the Diagnostic Accuracy of Chromogranin A in Detecting Patients with Neuroendocrine Tumors*

PW **(H9)** **Lamarca A et al.** *PD-1, PD-L1 and PD-L2 Expression in Well-Differentiated Small Bowel Gastrointestinal Neuroendocrine Tumours (Wd SB-NETs)*

(H10) **Lindquist D et al.** *LRIG1 was Down-Regulated in Medullary Thyroid Cancer but no Significant Effect of LRIG1 Was Found in RET2B Transgenic Mice and Human Differentiated Thyroid Cancer*

(H11) **Lv Y et al.** *The Diagnostic and Prognostic Value of Plasma CgA in Nonfunctional Pancreatic Neuroendocrine Neoplasms*

(H12) **Lv Y et al.** *The Exploration of the Clinical Value of Plasma CgA in Nonfunctional Gastroenteropancreatic Neuroendocrine Neoplasms*

(H13) **Lv Y et al.** *The Value of Plasma CgA Combined with NSE Performed As the Real-Time Monitor of Clinical Characteristics in Gastroenteropancreatic Neuroendocrine Neoplasms after the Resection of Primary Lesions*

(H14) **Meijer W et al.** *Clinical Correlates of Discrepant Results of Chromogranin A Versus Serotonin Markers in Patients with Neuroendocrine Tumors*

(H15) **Miki M et al.** *Utility of Serum Chromogranin B Compared with Chromogranin A as a Biomarker in Japanese Patients with Pancreatic Neuroendocrine Tumors*

(H16) **Tirosh A et al.** *24 Hour Urinary 5-Hydroxyindoleacetic Acid (5HIAA) and Vasoactive Intestinal Peptide (VIP) Doubling-Times (DTs) Predict Disease-Specific Mortality (DSM) in Patients with Neuroendocrine Tumors (NETs)*

(H17) **Tirosh A et al.** *Association between Neuroendocrine Tumors (NETs) Biomarkers and Tumor Burden Based on Total 68Ga-DOTATATE-Avid Tumor Volume (TV) Measurements*

(H18) **Tong Z et al.** *Preoperative Blood Neutrophil-To-Lymphocyte Ratio-Based Nomogram Predicts Lymph Node Metastasis in Patients of Resectable Pancreatic Neuroendocrine Tumors*

(H19) **Westin G et al.** *Metastatic Pancreatic Neuroendocrine Tumors (pNETs) and Primary Tumor Resection: A NCDB Survival Evaluation*

SCIENTIFIC PROGRAM

I. IMAGING (RADIOLOGY, NUCLEAR MEDICINE, ENDOSCOPY)

(I1) *Aalbersberg E et al. Distribution of 68Ga-HA-DOTATATE and 68Ga-DOTATATE in 343 Patients: Not the Same after All*

(I2) *Antwi A et al. Sensitivity of Glucagon-Like Peptide-1 Receptor (GLP1-R) SPECT/CT, PET/CT and MRI for the Localization of Benign Insulinomas: Interim Analysis of a Prospective Imaging Efficacy Study*

OA **(I3)** *Binderup T et al. FDG-PET Is Superior to WHO Grading in Predicting Overall Survival of Patients with Neuroendocrine Tumors: A Prospective Study of 172 Patients*

(I4) *Boss M et al. 68Ga-NODAGA-exendin-4 PET/CT for the Localization of Insulinomas: Preliminary Data from a Prospective Multicenter Imaging Study*

(I5) *Jenkins C et al. Diffusion Weighted Imaging as a Screening Tool in the Detection and Monitoring of Pancreatic Neuroendocrine Tumours in Patients with Familial Cancer Syndromes*

(I6) *Konsek S et al. Value of Somatostatin Receptor Imaging (SRI) in Patients with Appendiceal Neuroendocrine Neoplasms (ANEN) Base on Clinical Follow-Up*

(I7) *Lin X et al. Ultrasonography Characteristics of Hepatic Neuroendocrine Neoplasm*

(I8) *Lin X et al. Application of Parametric Contrast-Enhanced Ultrasound for Early Treatment Response Evaluation in Metastatic Hepatic Neuroendocrine Neoplasm*

(I9) *Manoharan P et al. Safety and Tolerability of „Ready-to-Use" (SOMAKIT TOC®) 68Ga-DOTA0-Tyr3-Octreotide (68Ga-DOTATOC) for Injection in Patients with Proven Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs)*

(I10) *Massironi S et al. Endoscopic Ultrasound Appearance of Pancreatic Serotonin-Staining Neuroendocrine Neoplasms: A Case Series*

(I11) *Rodrigues M et al. 68Ga-DOTA-TOC and 18F-FDG-PET/CT in the Follow-up of NET Patients Treated with First Full PRRT*

(I12) *Sato A et al. 18F-FDG-PET to Discriminate Biologically Malignant Pancreatic Neuroendocrine Tumors*

(I13) *Solis-Hernandez MP et al. Radiological Changes in the Treatment of Pancreatic Neuroendocrine Tumors (PNET) with Sunitinib: RECIST vs CHOI Criteria. CRIPNET-GETNE Study*

(I14) *Ueda K et al. Should the Selective Arterial Secretagogue Injection Test for Insulinoma Localization be Evaluated at 60 Seconds or at 120 Seconds?*

(I15) *Werner R et al. Triple Tracer Imaging Approach for the Non-Invasive Assessment of Chemokine Receptor 4 Expression in Gastroenteropancreatic Neuroendocrine Tumors*

(I16) *Yu J et al. An Intrapatient Comparison of 18FDG and 68Ga-DOTA-TATE PET/CT Imaging in Patients with Gastrointestinal Neuroendocrine Neoplasm*

(I17) *Zhang P et al. A Comparison of 68Ga-DOTA-TATE and 18F-FDG PET/CT Imaging on Patients with Pancreatic Neuroendocrine Neoplasm (pNEN)*

(I18) *Zilli A et al. Shear Wave Elastography Imaging in Neuroendocrine Liver Metastases: Preliminary Data from a Single Center*

J. MEDICAL TREATMENT – CHEMOTHERAPY, MEDICAL TREATMENT - OTHERS

(J1) *Ali J et al. The Characteristics and Survivals of Gastrointestinal Neuroendocrine Tumors, A Single Center Experience from Developing Country*

(J2) *Antista M et al. Effectiveness of Chemoterapy in Advanced PanNETs with ki67<55%: Monocentric Experience*

(J3) *Chen Z et al. FOLFIRI Regimen with or without Bevacizumab As Second-Line Therapy Showed Activity in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma*

(J4) *de Mestier L et al. 5-Fluorouracile Plus Dacarbazine in Metastatic Digestive Neuroendoendocrine Tumors: Efficacy and Potential Biomarkers*

PW **(J5)** *Derks J et al. Chemotherapy for Pulmonary Large Cell Neuroendocrine Carcinomas: Does the Regimen Matter?*

(J6) *Foulfoin F et al. Treatment of Metastatic Pancreatic Neuroendocrine Tumors: Relevance of ENETS 2016 Guidelines*

(J7) *Hijioka S et al. Pancreatic NET-G3 Does Not Respond to Platinum-Based Chemotherapy: A Multicenter Study of Neuroendocrine Carcinomas*

(J8) *Lepage C et al. REMINET: A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors*

Legend: *Selected for: Oral Abstract* **OA** */ Presidential Abstract* **PA** */ Poster Walks* **PW** */ ENETS/NANETS Young Investigator Symposium* **E/N**

(J9) **Yihebali C et al.** *A Study of S1/Temozolomide (STEM) Regimen in Patients with Metastatic Neuroendocrine Tumors*

(J10) **Yoo C et al.** *Clinical Outcomes of Systemic Chemotherapy in Patients with High Grade Neuroendocrine Carcinoma of Biliary Tract*

K. MEDICAL TREATMENT - SMS ANALOGUES, INTERFERON

PW **(K1)** **Albertelli M et al.** *Safety and Efficacy of High Doses Lanreotide Treatment in Patients with Progressive Neuroendocrine Tumors: Results from a Prospective Phase II Trial*

(K2) **Almquist M et al.** *STREET - Somatostatin Treatment Experience Trial*

(K3) **Bengueddach A et al.** *Therapeutic Strategies in Patients with Neuroendocrine Neoplasm: 30 Month Follow-Up pf Long Survivors from EPH Mostaganem and EHU Oran Medical Oncology*

(K4) **Chan D et al.** *Escalated Dose Somatostatin Analogues for Anti-Proliferative Effect in Gastroenteropancreatic Neuroendocrine Tumours (GEPNETS): A Systematic Review*

(K5) **Duchateau L et al.** *An Exploratory Patient Centric Analysis of the ELECT Trial: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel/Depot (LAN) Treatment for Patients (pts) with Carcinoid Syndrome (CS)*

(K6) **Elgendy K et al.** *Perioperative Carcinoid Crisis during Surgery- Who Benefits from Octreotide?*

(K7) **Ferolla P et al.** *Open-Label Multicentre Single-Arm Phase 2 Trial of Lanreotide Autogel (LAN) in Combination with Temozolomide (TMZ) in Patients with Advanced Well/Moderately Differentiated Neuroendocrine Tumours (NETs) of Lung and Thymus: ATLANT*

(K8) **Foltyn W et al.** *Effect of Treatment with Prolonged-Release Somatostatin Analogues on the Concentration of Serum Fibrosis Markers in Patients with Carcinoid Syndrome*

(K9) **Geilvoet W et al.** *Patient Satisfaction Regarding Home Injection Service for Somatostatin Analogues: A Survey among Patients with a Neuroendocrine Tumour*

(K10) **Li YL et al.** *Role of SSA in the Management of Multiple Type 1 Gastric Neuroendocrine Neoplasms*

(K11) **Luo Y et al.** *Optimisation of the Size Variation Threshold for CT Evaluation of Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors Treated with Octreotide LAR*

OA **(K12)** **Martínez-López A et al.** *Efficacy of Lanreotide (LAN), Both Alone and in Combination with Targeted Therapies in a Preclinical Model of Pancreatic Neuroendocrine Tumors (pNETs)*

(K13) **Modica R et al.** *Somatostatin Analogs in Patients with Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndrome: Efficacy and Safety*

(K14) **Pavel M et al.** *Results from a Phase 2, Open-Label, Multicenter, Randomized Study of the Novel, Octreotide (Oct) Subcutaneous (SC) Depot Formulation in Patients with Functioning Neuroendocrine Tumors (NETs) and Acromegaly Previously Treated with Long-Acting Octreotide*

(K15) **Pavel M et al.** *Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Patients with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: The Prospective, Open-label, International, Phase 2 CLARINET FORTE Study*

PW **(K16)** **Pavel M et al.** *Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial*

(K17) **Phan AT et al.** *Safety and Tolerability of Lanreotide Autogel/Depot (LAN) in Patients (pts) with Neuroendocrine Tumours (NETs): Pooled Analysis of Clinical Studies*

(K18) **Phan AT et al.** *Long-Term Efficacy and Safety with Lanreotide Autogel/Depot (LAN) from CLARINET and Open-Label Extension (OLE) Studies*

(K19) **Prinzi N et al.** *Safety of Lanreotide 120 mg ATG (LAN) in Combination with Metformin (MET) in Patients (pts) with Progressive Advanced Well-Differentiated (WD) Gastro-Intestinal (GI) or Lung Carcinoids. A Pilot, One-Arm, Open-Label, Prospective Study: The MetNET-2 Trial*

(K20) **Reidy-Lagunes D et al.** *Lanreotide Autogel/Depot (LAN) in Lung Neuroendocrine Tumours (NETs): The Randomized, Double-Blind, Placebo (PBO)-Controlled, International Phase 3 SPINET Study*

(K21) **Voronkova IA et al.** *Somatostatin Receptor Expression in Adrenocortical Carcinoma*

L. MEDICAL TREATMENT - TARGETED THERAPIES

(L1) **Allen E et al.** *Metabolic Adaptation to Anti-Angiogenic Therapy*

(L2) **Anthony L et al.** *Impact of Concomitant Medication on Efficacy of Telotristat Ethyl – A Post Hoc Subgroup Analysis of the Phase 3 TELESTAR Study in Carcinoid Syndrome*

SCIENTIFIC PROGRAM

SCIENTIFIC PROGRAM

(L3)   **Djihed B et al.** *Sunitinib as First Line Therapy in Patients with Advanced Pancreatic Neuroendocrine Tumors: Experience of a Single Algerian Center*

(L4)   **Eslick E et al.** *Towards Personalizing PRRT with [177Lu]-Dotatate to Minimise Renal Toxicity in Neuroendocrine Tumour Patients*

(L5)   **Kouzminov A et al.** *Comparative Retrospective Analysis of pNETs Treatment with Everolimus (E) and Sunitinib (S)*

(L6)   **Lamarca A et al.** *Determination of an Optimal Response Cut-Off to Predict Progression-Free Survival(PFS) in Patients(pts) with Well-Differentiated Advanced Pancreatic Neuroendocrine Tumours(pNETs) Treated with Sunitinib(S): An Alternative to the Current RECIST-Response*

(L7)   **Lapuerta P et al.** *Integrated Safety Analysis of Telotristat Ethyl in Patients with Carcinoid Heart Disease*

(L8)   **Luca R et al.** *Use of Tyrosine-Kinase Inhibitors in Medullary Thyroid Carcinoma: An Institutional Experience*

(L9)   **Mai R et al.** *Evaluation of the Somatostatin and CXCR4 Chemokine Receptor Expression in Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN) of Different Origin*

(L10)   **Marconcini R et al.** *Sunitinib (Su) in Progressive Pancreatic Neuroendocrine Tumor (PNET) Administered in Different Treatment Lines*

(L11)   **Milanetto AC et al.** *Multimodal Treatment of a Metastatic Pancreatic NeuroEndocrine Tumor in Von Hippel Lindau Disease*

(L12)   **Modica R et al.** *Efficacy and Safety of Low Dose Vandetanib in Metastatic Medullary Thyroid Cancer*

(L13)   **Pérez de la Puente C et al.** *Targeted Therapies (TT) (Sunitinib and Everolimus) for Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET). A Case Series*

(L14)   **Quaglia E et al.** *A Qualitative Exploration into the Experience of Neuroendocrine Pancreatic Cancer Patients Receiving Molecular Targeted Therapies*

(L15)   **Raymond E et al.** *The Efficacy and Safety of Sunitinib in Patients with Advanced Well Differentiated Pancreatic Neuroendocrine Tumors: Focus on Response Rate*

(L16)   **Solis-Hernandez MP et al.** *Clinical Features and Outcomes of Advanced PNETs Treated with Sunitinib: Data from CRIPNET-GETNE Study*

E/N (L17)   **Weis C et al.** *GSK3: A Novel Therapeutic Target in NETs?*

PA (L18)   **Xu JM et al.** *An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967)*

(L19)   **Yao JC et al.** *An Open-Label Phase II Study to Evaluate the Efficacy and Safety Of PDR001 in Patients with Advanced Well-Differentiated Non-Functional NET of Pancreatic, Gastrointestinal (GI), or Thoracic Origin Who Have Progressed on Prior Treatment*

M. MEDICAL TREATMENT - OTHERS

(M1)   **Alexandraki K et al.** *Biphosphonates in Metastatic Bone Disease of Neuroendocrine Neoplasms*

PW (M2)   **Apostolidis L et al.** *Skeletal-Related Events (SREs) and Use of Antiresorptive Therapy (ART) in Patients with Bone Metastases of Neuroendocrine Neoplasms*

(M3)   **Cella D et al.** *Relationship Between Symptoms and HRQoL Benefits in Patients (pts) with Carcinoid Syndrome (CS): A Post-Hoc Analysis of Telotristat Ethyl (TE) TELESTAR Trial*

(M4)   **De Hosson LD et al.** *Towards Optimal Personalized Diet and Vitamin Supplementation in NET Patients; A Feasibility Study*

(M5)   **De Hosson LD et al.** *Web-Based Tailored Information and Support for Patients with a Neuroendocrine Tumor*

(M6)   **Goetghebeur M et al.** *To Treat or Watch? Identifying Drivers of Decisions for Patients with GEP-NET Using Reflective Multi-Criteria Decision Analysis*

(M7)   **Kim S et al.** *The Impact of the Pathologic Differentiation (Well or Poorly) and the Degree of Ki-67 Index in Patients with Metastatic WHO Grade 3 GEP-NETs*

PW (M8)   **Pavel M et al.** *Correlation of Plasma (p) and Urine (u) 5-HIAA Levels in Patients (pts) with Carcinoid Syndrome (CS) – Post-Hoc Analyses from the TELESTAR Study*

(M9)   **Vaslamatzis M et al.** *Metachronous Pancreatic Neuroendocrine Tumors. An Unusual Interesting Case Report*

N. PRRT-ABLATIVE THERAPIES- ENDOSCOPIC TREATMENT, SURGICAL TREATMENT

(N1) **Blanco C et al.** *Selective Transarterial Embolization of Gastro-Entero Pancreatic (GEP) Neuroendocrine Tumors (NET) with Advanced Locoregional Disease and/or Liver Metastases*

PW (N2) **Bodei L et al.** *Circulating Neuroendocrine Transcripts and Gene Cluster Analysis Predict the Efficacy of PRRT*

PA (N3) **Braat A et al.** *International Multicenter Retrospective Study on the Efficacy and Toxicity of Radioembolization in Neuroendocrine Tumours with Yttrium-90 Resin Microspheres*

(N4) **Brabander T et al.** *Pitfalls in the Response Evaluation after Peptide Receptor Radionuclide Therapy with [177Lu-DOTA0,Tyr3]Octreotate*

(N5) **Demetriou G et al.** *Predictors of Outcome in Patients Treated with Peptide Radio-Labelled Receptor Target Therapy (PRRT)*

(N6) **Dureja S et al.** *Dosimetric Analyses of Patients with Metastatic Gastrointestinal Neuroendocrine Tumors Treated with PRCRT Using 177 Lu-DOTATATE with Capecitabine as Radiosensitizer*

(N7) **Fong M et al.** *Initial Experience of a Novel Endoscopic Full Thickness Resection Device (FTRD) for the Treatment of Rectal Neuroendocrine Tumours*

(N8) **Genov J et al.** *Eleven Years Survival after Combined Treatment of Surgery, Ultrasound-Guided Radiofrequency Ablation of Liver Metastasis, CT Embolization Plus Somatostatin LAR in a Case with Atypical Carcinoid of the Lung*

(N9) **Kidd M et al.** *A Hybrid Clinical Molecular Nomogram Accurately Predicts Survival in PRRT Treated GEP-NETs*

(N10) **Kluge A et al.** *Predictive Value of Baseline Hematology Parameters on Outcome of 177Lu-DOTATOC PRRT*

(N11) **Kong G et al.** *Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Functional and Metastatic Phaeochromocytoma (PCC) and Paraganglioma (PGL)*

(N12) **Nicolas G et al.** *Peptide Receptor Radionuclide Therapy (PRRT) with a Somatostatin Receptor (SSTR) Antagonist in Patients with SSTR-Positive, Progressive Neuroendocrine Tumours (NETs): A Phase I/II Open-Label Trial to Evaluate the Safety and Preliminary Efficacy of 177Lu-O*

(N13) **Nowicki ML et al.** *Survival Analysis after i.a. 90Y-DOTATATE PRRT, in Patients with Non-Resectable, Advanced, Progressive, Liver-Dominant Neuroendocrine Neoplasms*

(N14) **Patel D et al.** *The Effect of PRRT on Health-Related Quality of Life in NET Patients: A Prospective Study*

(N15) **Prasad V et al.** *Lanreotide Autogel/Depot (LAN) in Combination with Peptide Receptor Radionuclide Therapy (PRRT) in Progressive Digestive and Lung Neuroendocrine Tumours (NETs): Design of the PRELUDE Study*

PW (N16) **Smit Duijzentkunst D et al.** *Treatment of Paragangliomas with Lutetium-177-Octreotate Based Peptide Receptor Radionuclide Therapy*

(N17) **Sousa V et al.** *A Nuclear Combination in Heterogeneous Metastatic Neuroendocrine Tumors*

(N18) **Steyn R et al.** *Peptide Receptor Radionuclide Therapy in a Patient with SDHB Related Grade 3 Parag anglioma (PGL) of Urinary Bladder*

OA (N19) **Strosberg J et al.** *NETTER-1 Phase III Trial: Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors*

(N20) **Yordanova A et al.** *Survival Analysis of Combined Therapy with 177Lu-Octreotate and Somatostatin Analogues in Advanced Metastatic Neuroendocrine Tumours*

O. SURGICAL TREATMENT

(O1) **Begum N et al.** *Study Protocol: Prospective, Randomized Controlled Trial on the Effect of Primary Resection in Advanced Metastatic NEN of Pancreas and Midgut (PRESNENAS)*

PA (O2) **Benhaim L et al.** *Comparison of Long Terms Outcomes after Resection of Hepatic and /or Peritoneal Metastasis from Neuroendocrine Tumors*

(O3) **Chan D et al.** *Trans-Anal Minimally Invasive Surgery (TAMIS) for Completion Local Excision of Well-Differentiated Rectal Neuroendocrine Tumours*

PW (O4) **Coppa J et al.** *Conditional Survival (CS) Analysis of Liver Resection (LR) for Gastro-Entero-Pancreatic Neuroendocrine Tumor (GEP-NET)*

(O5) **Damoli I et al.** *Laparoscopic and Robotic Resection for Pancreatic Neuroendocrine Tumors (pNET): Less Is More?*

SCIENTIFIC PROGRAM

(O6) **Galleberg RB et al.** *Resection of Liver Metastases in Patients with High-GradeGastroenteropancreatic Neuroendocrine Carcinomas: A Nordic Multicenter Study*

(O7) **Guo J et al.** *Should Surgery Be Conducted for Small Nonfunctioning Pancreatic Neuroendocrine Tumors: A Systemic Review*

(O8) **Guo J et al.** *Systematic Review of Resecting Primary Tumor in MNETs Patients with Unresectable Liver Metastases*

(O9) **Jaber B et al.** *Patient Outcomes after Cardiac Surgery for Carcinoid Heart Disease Are Dependant Upon Successful Cytoreductive Multimodal Treatment and Control of Metastatic Neuroendocrine Disease*

(O10) **Kaemmerer D et al.** *Primary Tumor Resection Results in Superior Overall Survival after Peptide Receptor Radionuclide Therapy in Advanced Neuroendocrine Neoplasms*

(O11) **Kaldarov A et al.** *Selective Approach in Surgical Treatment of Pancreatic Neuroendocrine Tumors*

(O12) **Klein F et al.** *Prognostic Factors for Long-Term Survival in 102 Consecutive Pancreatic Resections for Primary Neuroendocrine Tumor*

(O13) **Malpaga A et al.** *18F-FDG Positron Emission Tomography/Computed Tomography Positivity in Small Incidentally-Found Pancreatic Neuroendocrine Tumors: Could It Be Considered a Predictor of Malignancy?*

(O14) **Marchegiani G et al.** *Are Cystic Pancreatic Neuroendocrine Tumors an Indolent Entity? Results for a Single Institutional Surgical Series*

(O15) **Massani M et al.** *Surgical Strategies and Selection Criteria for Patients with Liver Metastasis from Neuroendocrine Tumors: Personal Experience*

(O16) **Milione M et al.** *Ki67 Is Able to Predict Pancreatic NENs Prognosis Irrespective of Their Size*

PA **(O17)** **Mills L et al.** *Tumour Size Is not a Reliable Criterion for Resection of Patients with Non-Secreting Pancreatic Neuroendocrine Tumours: Results of an International, Multi-Centre, Operative Cohort*

(O18) **Modlin I et al.** *Measurement in Blood of a Circulating NET mRNA Gene to Predict Surgical Efficacy*

(O19) **Muffatti F et al.** *Outcome of Surgical Resection after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT) for Pancreatic Neuroendocrine Neoplasms: A Case-Matched Analysis*

PW **(O20)** **Nell S et al.** *Management of MEN1 Related Non-Functioning Pancreatic NETs: A Shifting Paradigm. Results from the DutchMEN1 Study Group*

(O21) **Nell S et al.** *Minimal Risk of Persistent or Recurrent Hypoglycemia after MEN1-Related Insulinoma Surgery. A Large International Cohort Study*

(O22) **Raja K et al.** *Gallbladder Neuroendocrine Carcinoma. Is it Different from Adenocarcinoma?*

(O23) **Rota R et al.** *FNA Under Percutaneous Ultrasound or Endoscopic Ultrasound for Pre-Operative Diagnosis and Grading Determination in PanNET. Are They Reliable to Define a Tailored Therapy?*

OA **(O24)** **Sallinen V et al.** *Prognosis of Sporadic Resected Small (≤ 2 cm) Nonfunctional Pancreatic Neuroendocrine Neoplasms - A Multi-Institutional Study*

(O25) **Yuan C et al.** *Meta-Analysis of Liver Resection versus Nonsurgical Treatments for Pancreatic Neuroendocrine Tumors with Liver Metastases*

P. NON DIGESTIVE NETS (BRONCHIAL, MTC PHEOCHROMOCYTOMA) PATHOLOGY, GRADING, STAGING

(P1) **Delektorskaya V et al.** *Expression and Clinical Significance of Somatostatin Receptor Subtype 2A in Small Cell Lung Carcinoma*

(P2) **Demirovic A et al.** *Primary Neuroendocrine Carcinoma of the Breast: A Diagnostic Approach to the Special Type of Breast Malignancy*

(P3) **Lewczuk A et al.** *Utility of a Circulating NET mRNA Gene Signature for Defining Bronchopulmonary Neuroendocrine Neoplasia and Evaluating Disease Progression*

(P4) **Westin G et al.** *Renal Neuroendocrine Tumors (rNETs): A Single-Center Experience*

(P5) **Zanata I et al.** *Lung Carcinoid: Role of NSE and Imaging Techniques in Long-Term Follow-Up of Malignancy Recurrence*

Legend: Selected for: Oral Abstract OA/ Presidential Abstract PA/ Poster Walks PW/ ENETS/NANETS Young Investigator Symposium E/N

Q. CLINICAL CASES/REPORTS

(Q1) **Baki S et al.** *Primary Hyperparathyroidism in Pregnancy: A Case Report*

(Q2) **Bima C et al.** *Un Unusual Tumor Association in Acromegaly*

(Q3) **Boss M et al.** *Detection of Metastatic Insulinoma with 68Ga-NODAGA-Exendin-4 PET/CT in a Young Child – A Case Report*

(Q4) **Chi Y et al.** *Pure Alpha-Fetoprotein-Producing Pancreatic Neuroendocrine Tumors: A Case Report*

(Q5) **Croitoru A et al.** *Large Cell Metastatic Pancreatic Neuroendocrine Carcinoma Treated with Somatostatin Analogues*

(Q6) **Croitoru A et al.** *Small Cell Metastatic Ascending Colon Neuroendocrine Carcinoma*

(Q7) **Dawes A et al.** *Sinonasal Neuroendocrine Small Blue Cell Tumour (SNBCT) Presenting with Bone Marrow Failure – A Very Rare Diagnostic and Therapeutic Challenge*

(Q8) **Dermine A et al.** *A Case with Multiple Neuroendocrine Tumors*

(Q9) **Deslé M et al.** *Hypoglycemias Appearing in a Patient Suffering from Poorly Differentiated Neuroendocrine Tumor for Three Years*

(Q10) **Fatima A et al.** *Presentation of a Neuroendocrine Tumor of Breast in a Pakistani Nulliparous Woman*

(Q11) **Femia D et al.** *A Long-Term Complete Response (CR) of Avelumab in Patient (pt) with Advanced Merkel Cell Carcinoma (MCC)*

(Q12) **Frilling A et al.** *Multivisceral Transplantation and Vascularised Sentinel Forearm Flap for a Metastatic Small Bowel Neuroendocrine Tumour: Update on Follow-Up*

(Q13) **Grego E et al.** *Prostate-Specific Membrane Antigen (PSMA) Uptake in a Pancreatic Neuroendocrine Tumor (pNET) Bearing Patient*

(Q14) **Grego E et al.** *New MEN-1 Gene Mutation Implicated in Familiar MEN-1 Syndrome Onset*

(Q15) **Hong SM et al.** *Incidentally Detected Pancreatic Neuroendocrine Microadenoma with Lymph Node Metastasis*

(Q16) **Lambrescu IM et al.** *SDHB Mutation in a Young Patient with a Metastatic Paraganglioma of the Urinary Bladder*

(Q17) **Liço V et al.** *Unusual Presentation of Carcinoid Syndrome in Chronic Pancreatitis*

(Q18) **Linder Ekberg K et al.** *SSA-, H1, H2- and Leukotriene Receptor Blockade Eliminates Handicapping Symptoms from Atypical Carcinoid Syndrome*

(Q19) **Marques B et al.** *Recurrence of 6mm Rectal Neuroendocrine Tumor, 14 Years after Excision*

(Q20) **Marques B et al.** *Yttrium-90 Radioembolization for Progressive Medullary Thyroid Carcinoma with Exclusive Liver Metastasis*

(Q22) **Martins D et al.** *Follow-Up in Neuroendocrine Neoplasms: Can Chromogranin A Be the Confounder?*

(Q23) **Nakano K et al.** *A Case Report of NET G1 of the Gallbladder*

(Q24) **Muller N et al.** *Portal Hypertension-Related Digestive Hemorrhage in Patients with Pancreatic Neuroendocrine Tumors*

(Q25) **Prinzi N et al.** *Outstanding Response to Sunitinib in a Patient with Unresectable Retroperitoneal Paraganglioma*

(Q26) **Sagar V et al.** *A Single Centre Analysis of the Management of Appendiceal Neuroendocrine Neoplasms (NENs) Including Goblet Cell Carcinoids (GCC)*

(Q27) **Sagar V et al.** *A Case Report of Bicaval Stents and Inferior Vena Cava Valve Implantation to Control Carcinoid Symptoms in Order to Safely Allow Surgical Valve Replacement*

(Q28) **Satoshi K et al.** *Outcomes of Hepatobiliary Neuroendocrine Neoplasms Treated with Systemic Therapy: A Retrospective Analysis*

(Q29) **Smiroldo V et al.** *Complete Remission of Hepatic Metastasis after Total Gastrectomy for a Gastric Carcinoid Tumor Type 1: A Case Report*

(Q30) **Stavrides-Eid M et al.** *Case Study: Immunotherapy in a Young Adult with Atypical Neuroendocrine Tumour*

(Q31) **Steina L et al.** *A Rare Case of Ectopic Cushing's Syndrome*

(Q32) **Strzelczyk J et al.** *Over Treatment Radionuclide Therapy (PRRT) of Metastatic Neuroendocrine Neoplasm (NEN) – A Case Report*

(Q33)   **Tang X et al.** *Clinicopathological Features and Survival Analysis of 98 Patients with Gastroenteropancreatic Neuroendocrine Neoplasms*

(Q34)   **Trifanescu R et al.** *Acute Somatostatin Analog Suppression Test in a Patient with Thyrotropin-secreting Pituitary Macroadenoma*

(Q35)   **Uchida Y et al.** *A Successful Case of Controlling the Multiple Distant Metastasis of Pancreatic G2 NET with Local Therapy Combined with Systemic Pharmacotherapy*

(Q36)   **van Fraeyenhove F et al.** *Tumor Growth Rate to Assess Tumor Activity in Patients with Lung Neuroendocrine Tumors on Lanreotide Autogel: A Case-Series Analysis*

(Q37)   **Zingaretti CC et al.** *Sporadic Panglandular Non-Functioning pNET: New Entities? A Case Series*

R. ...NONE OF THE ABOVE

(R1)   **Bouma G et al.** *Videoconsultation During Follow-Up Care of Patients with a Neuroendocrine Tumor*

(R2)   **Chan D et al.** *External Beam Radiotherapy (EBRT) in the Treatment of Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review*

(R3)   **Davies P et al.** *Pilot Electronic Survey to Locate Nurses Caring for NET Patients in Europe*

(R4)   **Djihed B et al.** *Neuroendocrine Tumors: A Retrospective Analysis in a Single Algerien Institution*

(R5)   **Donnelly L et al.** *A Prospective Service Evaluation of Systematic Gastroenterological Assessment and Management on Patients with Neuroendocrine Tumours in South East Wales*

(R6)   **Fouché M et al.** *Intraoperative Carcinoid Syndrome During Small-Bowel NET Surgery: Description, Prevalence and Risk Factors*

PW (R7)   **Gallego J et al.** *On-going Evaluation of The Clinical Utility of the Health-Related Quality-Of-Life (HRQoL) QLQ-GINET21 Questionnaire (QNR) in the Treatment of Patients (pts) with Gastrointestinal (GI) Neuroendocrine Tumours (NETs). QUALINETS Study*

(R8)   **Goetghebeur M et al.** *What Matters Most? An Exploration of Decision Criteria Considered by Patients with GEP-NET and Physicians Using Holistic Multi-Criteria Decision Analysis*

(R9)   **Grozinsky-Glasberg S et al.** *The Role of Hepatic Trans-Arterial Chemoembolization in Metastatic Medullary Thyroid Carcinoma: A Specialist Center Experience and Review of the Literature*

(R10)   **Milanetto AC et al.** *NeuroEndocrine Tumors of The Ampullary Region: A Rare Challenging Entity*

(R11)   **Moody L et al.** *Optimising Followup after Complete Surgical Resection of Gastrointestinal Neuroendocrine Tumours- A Delphi Process to Produce Expert Consensus in an Area Lacking Clinical Evidence*

(R12)   **Plante A et al.** *Patient-Reported Preferences in Treatments Approved in Neuroendocrine Tumors: A National Survey from the French Group of Endocrine Tumors*

(R13)   **van Leeuwaarde R et al.** *Quality of Life in Patients with Multiple Endocrine Neoplasia Type I (MEN1): Results from the Dutch MEN1 Study Group*

SCIENTIFIC PROGRAM

Legend: *Selected for: Oral Abstract* OA*/ Presidential Abstract* PA*/ Poster Walks* PW */ ENETS/NANETS Young Investigator Symposium* E/N

Faculty List

Elizabeth	Allen	SUI	Ron	Hollander	USA
Richard P.	Baum	GER	Dieter	Hörsch	GER
Jorge	Barriuso	GBR	Henning	Jann	GER
Detlef	Bartsch	GER	Robert	Jensen	USA
Eric	Baudin	FRA	Gregory	Kaltsas	GRE
Léonor	Benhaim	FRA	Reza	Kianmanesh	FRA
Jonathan	Benhamou	FRA	Andreas	Kjaer	DEN
Ruben	Bill	SUI	Günter	Klöppel	GER
Lisa	Bodei	USA	Ulrich	Knigge	DEN
Julien	Bollard	FRA	Teodora	Kolarova	BUL
Ivan	Borbath	BEL	Beata	Kos-Kudła	POL
Catherine	Bouvier	GBR	Guenter	Krejs	AUT
Arthur	Braat	NED	Sebastian	Krug	GER
Giulia	Bresciani	ITA	Matthew	Kulke	USA
Jaume	Capdevila	ESP	Marnix G. E. H.	Lam	NED
Martyn	Caplin	GBR	Konstantinos	Leventakos	USA
Oriol	Casanovas	ESP	Simone	Leyden	AUS
Leandro	Castellano	GBR	Su-Chen	Li	SWE
Mauro	Cives	ITA	Michal	Lotem	ISR
Frederico	Costa	BRA	Yoshiyuki	Majima	JPN
Anne	Couvelard	FRA	Ilaria	Marinoni	SUI
Joakim	Crona	SWE	Eletttra	Merola	ITA
Jerome	Cros	FRA	David	Metz	USA
Jaroslaw	Ćwikła	POL	Logan	Mills	GBR
Arvind	Dasari	USA	Bruno	Niederle	AUT
Joseph	Davar	GBR	Els	Nieveen van Dijkum	NED
Philippa	Davies	GBR	Svenja	Nölting	GER
Thierry	de Baère	FRA	Kjell	Öberg	SWE
Wouter W.	de Herder	NED	Juan	O'Connor	ARG
Clarisse	Dromain	FRA	Dermot	O'Toole	IRL
Jan	Dumanski	SWE	Ulrich-Frank	Pape	GER
Sugandha	Dureja	IND	Stefano	Partelli	ITA
Barbro	Eriksson	SWE	Andreas	Pascher	GER
Massimo	Falconi	ITA	Marianne	Pavel	GER
Jenny	Falkerby	SWE	Marc	Peeters	BEL
Nicola	Fazio	ITA	Stephen	Pereira	GBR
Diego	Ferone	ITA	Aurel	Perren	SUI
George	Fisher	USA	Lise Munk	Plum	DEN
Andrea	Frilling	GBR	Elizabeth	Quaglia	GBR
Rocio	Garcia-Carbonero	ESP	Nitya	Raj	USA
Sebastien	Gaujoux	FRA	John	Ramage	GBR
Bernhard	Gebauer	GER	Eric	Raymond	FRA
Wanda	Geilvoet	NED	Nick	Reed	GBR
Simona	Glasberg	ISR	Guido	Rindi	ITA
Vera	Gorbunova	RUS	Anja	Rinke	GER
Enrique	Grande	ESP	Philippe	Ruszniewski	FRA
Ashley	Grossman	GBR	Alan	Sag	TUR
Marion	Hendriks de Jong	NED	Charalampos	Saganas	SUI
Rodney	Hicks	AUS	Ramon	Salazar	ESP
Leo	Hofland	NED	Alain	Sauvanet	FRA

Faculty List (continued)

Aldo	Scarpa	ITA	Christos	Toumpanakis	GBR
Joerg	Schrader	GER	Juan	Valle	GBR
Jean-Yves	Scoazec	FRA	Chris	Verslype	BEL
Kjerstin	Skrede Mordal	NOR	Valérie	Vilgrain	FRA
Halfdan	Sørbye	NOR	Marco	Volante	ITA
Ernst-Jan	Speel	NED	Marie-Pierre	Vullierme	FRA
Raj	Srirajaskanthan	GBR	Staffan	Welin	SWE
Thomas	Steinmüller	ITA	Gustavo	Westin	USA
Jonathan	Strosberg	USA	Tara L.	Whyand	GBR
Anders	Sundin	SWE	Bertram	Wiedenmann	GER
Mike	Tadman	GBR	Damian	Wild	SUI
Rajesh	Thakker	GBR	David	Wyld	AUS
Christina	Thirlwell	GBR	Jian Ming	Xu	CHN
Eva	Tiensuu Janson	SWE	James	Yao	USA
Amit	Tirosh	USA	Wouter	Zandee	NED

SCIENTIFIC PROGRAM

End of Scientific Program

Wednesday, 8 March 2017

The Centers of Excellence (CoE) Workshop Training Course is taking place within the framework of the 14th Annual ENETS Conference. Limited seats, prior online registration required.
The UEMS - EACCME® has granted 3 CME credits for this event.

Time: 11:00 - 14:00

Time	Topic	Room
	ENETS Centers of Excellence Workshop Training Course	132
10:00 - 11:00	**Registration**	
11:00 - 11:15	**Introduction** Overview: CoE Procedure - 8 Years of Experience *Dermot O'Toole, IRL* *Chairman of the ENETS CoE Certification Commission*	
11:15 - 12:45	**Aims, Basic Principles and Definitions** **ENETS CoE - Certification Procedure** • **Application** • **Enrolment** **Fundamentals of the Requirements Catalogue** **Presentation of Selected Documents** **Questions** *Regine Reinstorf, GER* *ENETS CoE Coordinator of the ENETS Certification* *Program for GSG – Cert*	
12:45 - 13:15	**ENETS CoE - Certification Procedure** • **Audit Preparation** • **What Has to Be Done between Enrolment and Onsite Audit?** **Questions** *Dermot O'Toole, IRL / Regine Reinstorf, GER* (Work & Lunch)	
13:15 - 13:45	**ENETS CoE - Certification Procedure** • **Onsite Audit** • **Deviations** *Dermot O'Toole, IRL / Regine Reinstorf, GER*	
13:40 - 14:00	**Feedback / Questions** *Dermot O'Toole, IRL / Regine Reinstorf, GER*	

(Coffee and tea will be offered during the entire workshop)

COE WORKSHOP

Industry - Sponsored Satellite Symposium I

IPSEN
Innovation for patient care

Leading the Way to Optimal Patient Care
A unique direction guided by a multidisciplinary team

12:45 - 14:15, Thursday, 9 March 2017

Speciality	Multidisciplinary Team	Room
Medical Oncologist (Chair)	*Nick Pavlakis* *Royal North Shore Hospital, Sydney, Australia*	112
Surgeon (Co-chair)	*Andrea Frilling* *Imperial College London, United Kingdom*	
Medical Oncologist	*Nicola Fazio* *European Institute of Oncology, Milan, Italy*	
	Alexandria T. Phan *University of New Mexico Comprehensive Cancer Center, Albuquerque, USA*	
Radiologist	*Maxime Ronot* *Hôpital Beaujon, Paris, France*	
Pathologist	*Günter Klöppel* *Technical University of Munich, Germany*	
Nurse	*Wanda Geilvoet* *Erasmus MC, Rotterdam, Netherlands*	

Come and join us on this journey to establish optimal treatment sequencing in NETs through an evolving case study, which will be discussed by an expert international multidisciplinary faculty.

Lunch boxes will be provided.

Industry - Sponsored Satellite Symposium II

NOVARTIS

Treating the Spectrum of NET: The Comprehensive Patient Journey

18:45 - 20:15, Thursday, 9 March 2017

Time	Topic	Room
18:45 - 18:50	**The Comprehensive NET Landscape - Knowledge Survey**	112
	Simron Singh (Chair)	
	Assistant Professor, University of Toronto, Odette Cancer Centre at Sunnybrook Health Sciences Centre, Toronto, Canada	
18:50 - 19:10	**The Spectrum of GI NET: Finding the Right Treatment for the Right Patient**	
	Diego Ferone	
	Professor of Endocrinology, Department of Internal Medicine & Medical Specialties Section of Endocrinology, University of Genoa, Genoa, Italy	
19:10 - 19:15	**Ask the Experts:**	
	Q&A All Faculty	
19:15 - 19:35	**Improving Lung NET Prognosis: Early Identification and Appropriate Management**	
	Nicola Fazio	
	Director of Gastrointestinal Medical Oncology and Neuroendocrine Tumors Unit, European Institute of Oncology [IEO], Milan, Italy	
19:35 - 19:40	**Ask the Experts:**	
	Q&A All Faculty	
19:40 - 20:00	**Long-Term Treatment of pNET: Optimizing the Patient Journey**	
	Simron Singh (Chair)	
	Assistant Professor, University of Toronto, Odette Cancer Centre at Sunnybrook Health Sciences Centre, Toronto, Canada	
20:00 - 20:05	**Ask the Experts:**	
	Q&A All Faculty	
20:05 - 20:15	**Perspectives on Best Practices for the Management of NET – Clinical Challenge Panel Discussion**	
	Q&A All Faculty	

A snack will be provided for attendees.

Industry - Sponsored Satellite Symposium III

The Expanding Arsenal of Therapeutic Strategies Against Gastroenteropancreatic Neuroendrocrine Tumors

07:00 - 08:30, Friday, 10 March 2017

Time	Topic	Room
07:00 - 07:25	**Arrival and Breakfast**	112
07:25 - 07:30	**Welcome, Introduction, and Knowledge Test** *Eric Baudin (Chair), Gustave Roussy, Villejuif, France*	
07:30 - 07:42	**Seeking Out the Enemy-New Developments in Imaging of GEP NETs** *Prakash Manoharan, The Christie Neuroendocrine Centre of Excellence, Manchester, United Kingdom*	
07:42 - 07:54	**Smart Weapons in the Management of GEP NETS** *Eric Baudin, (Chair), Gustave Roussy, Villejuif, France*	
07:54 - 08:08	**The Nuclear Option for GEP NETs** *Jaume Capdevila, Vall d'Hebron University Hospital, Barcelona, Spain*	
08:08 - 08:18	**Long-Term Safety of Peptide Receptor Radionuclide Therapy** *Tessa Brabander, Erasmus Medical Centre, Rotterdam, The Netherlands*	
08:18 - 08:28	**Questions and Faculty Discussion**	
08:28 - 08:30	**Looking Forward: prIME Points™ and Expert Recommendations** *Eric Baudin, (Chair), Gustave Roussy, Villejuif, France*	
08:30	**Adjourn**	

This educational activity is provided by prIME Oncology and supported by Advanced Accelerator Applications.

Breakfast will be provided for attendees.

Industry - Sponsored Satellite Symposium IV

Targeted Treatment of pNET:
New Long-Term and Real-World Evidence

12:50 - 14:20, Friday, 10 March 2017

Time	Topic	Room
12:50 - 12:55	**Welcome & Introduction** *Eric Raymond, France*	112
12:55 - 13:20	**Long-Term Impact on Patient Outcomes: 5 Years of Evidence** *Eric Raymond, France*	
13:20 - 13:50	**Real-World Data Supporting the Use of Targeted Therapy in Naïve and Pre-Treated Patients** *Ivan Borbath, Belgium*	
13:50 - 14:10	**Challenging conventional RECIST response: Application of a new cut-off for pNET** *Angela Lamarca, United Kingdom*	
14:10 - 14:20	**Practical Considerations and Conclusions** *Eric Raymond, France*	

Lunch boxes will be provided for attendees.

ENETS gratefully acknowledges the generous support of the sponsors

Platinum Sponsor

Legacy Sponsor

 &

Silver Sponsors

Industry - Sponsored Satellite Symposia

Symposium I

Leading the Way to Optimal Patient Care
A unique direction guided by a mulitdisciplinary team
Supported by IPSEN
Thursday, 9 March 2017, 12:45 - 14:15, Room 112

Symposium II

Treating the Spectrum of NET: The Comprehensive Patient Journey
Supported by Novartis Oncology
Thursday, 9 March 2017, 18:45 - 20:15, Room 112

Symposium III

The Expanding Arsenal of Therapeutic Strategies Against
Gastroenteropancreatic Neuroendrocrine Tumors
Supported by Advanced Accelerator Applications
Friday, 10 March 2017, 07:00 - 08:30, Room 112

Symposium IV

Targeted Treatment of pNET: New Long-Term and Real-World Evidence
Supported by Pfizer Oncology
Friday, 10 March 2017, 12:50 - 14:20, Room 112

Ground Floor
Level P0

Non-Profit Exhibitors:

B = Bioscientifica
N = NET Patient Foundation
6 = INCA / NET Research Foundation

ENETS:

P = Poster Help Desk / Poster Walks

Exhibitors:

1 = Ipsen
2 = Novartis
3 = Pfizer
4 = Advanced Accelerator Applications
5 = Sirtex
7 = Wisepress

Lunch &
Coffee Break
Area

Poster
Exhibition

P
B
N

5
6
7

3
4

1
2

Registration Desk

ENETS
Booth

e-Poster
Desk

e-Poster
Desk

Cloakroom

Evaluation
Desk /
Onsite
registration

Evaluation
Desk /
Onsite
registration

Evaluation
Desk /
Onsite
registration

Main Entrance

Introduction

ENETS 2016 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update

Dermot O'Toole[a]   Reza Kianmanesh[b]   Martyn Caplin[c]

[a]National Centre for Neuroendocrine Tumours, St. Vincent's University and Department of Clinical Medicine, St. James Hospital and Trinity College, Dublin, Ireland; [b]Department of Surgery, CHU Robert Debré, Reims, France; [c]Neuroendocrine Tumour Unit, Royal Free Hospital, London, UK

Several guidelines and standards of care on the management of neuroendocrine tumors (NETs) have been published by expert national and international groups in recent years [1–9]; additional changes in how these patients are managed are evolving rapidly, and since the last European Neuroendocrine Tumor Society (ENETS) Guidelines in 2011/12 [8], new important data have become available pertaining to novel diagnostic tools and therapies. On October 30th and 31st, 2014, the ENETS held an Advisory Board meeting in Vienna aiming at critically discussing and updating the ENETS Guidelines on the Diagnosis and Treatment of Neuroendocrine Tumors generated initially in 2005–2006 [2, 4] and revised in 2011 [8].

The consensus sessions covered the following neuroendocrine neoplasm-related topics by sites of origin or stage: gastroduodenal, midgut (including appendix), hindgut, functional pancreatic, non-functional pancreatic, and two final sessions that covered liver and other distant metastases from neuroendocrine neoplasms of any origin and a separate session devoted to neuroendocrine high-grade tumors and carcinomas.

How We Worked

The participants at the conference were asked to focus on the relevant literature published between 2011 and 2015. They met over two and a half days, in which data and new evidence were presented. The participants then retreated to break-out sessions according to their disciplines and were required to answer questions listed in a workbook created by the session chairs and the organizing committee. The workbook questions were tailored on the text of the initial guidelines framework [2, 4], focusing on the new available evidence. All relevant areas were updated via a thorough literature review and the questions that the chairpersons considered appropriate to discuss the new evidence. All participants were encouraged to challenge the document. Recent data on new evidence and insights were intensely discussed in working-group sessions as well as during the plenary session. Notes were taken continuously, so that the final agreement on each question was noted and returned to each session chair for preparation of the consensus statements. The magnitude of the consensus for each answer was estimated to achieve unanimity. In addition to providing textual guidelines, delegates were requested to elaborate accurate but simple

Prof. Dermot O'Toole
Department of Clinical Medicine and Gastroenterology
St. James Hospital and Trinity College
James's Street, Dublin 8 (Ireland)
E-Mail dermot.otoole@tcd.ie

Exhibitors, Patient Advocacy & Non-Profit Organizations

Exhibitors

ENETS greatly thanks all the exhibitors for sharing their knowledge, expertise and resources.

IPSEN — Innovation for patient care

NOVARTIS

Pfizer Oncology

Advanced Accelerator Applications — BRIDGING SCIENCE WITH LIFE

SIRTeX

w. wisepress.com — your medical bookshop

Patient Advocacy

ENETS kindly thanks the patient advocacy organizations for their presence and participation during the 14th Annual ENETS Conference 2017.

INCA — International Neuroendocrine Cancer Alliance

NET Patient Foundation

Non-Profit Organizations

ENETS also greatly appreciates and gives thanks to the presence and participation by the non-profit organizations during the 14th Annual ENETS Conference 2017.

ISI RESEARCH FOUNDATION — DEDICATED TO CURING NEUROENDOCRINE CANCER

bioscientifica

Profile

Ipsen is a global specialty-driven pharmaceutical group with total sales exceeding €1.4 billion in 2015. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases.

Its fields of expertise cover oncology, neurosciences and endocrinology (adult & pediatric). Ipsen's commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from neuro-endocrine tumors, prostate cancer, bladder cancer, pancreatic cancer and renal cancer. Ipsen also has a significant presence in primary care.

Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis/Paris-Saclay, France; Slough/Oxford, UK; Cambridge, US). In 2015, R&D expenditures neared €193 million.

The Group has more than 4,600 employees worldwide. Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and are eligible to the "Service de Règlement Différé" ("SRD"). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trades on the over-the-counter market in the United States under the symbol IPSEY.

For more information on Ipsen, visit www.ipsen.com.

2015 Key Figures

Drugs marketed in more than **115 countries**

Close to **3/4 of sales** generated by specialty **care drugs**

R&D expenditure close to **€193 million** representing about 15% of Group sales

3/4 of sales generated **outside** France

More than **4,600 employees** worldwide

IPSEN
Innovation for patient care

NOW ENROLLING

SPINET

An International **Phase 3**, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of **Lanreotide Autogel®/Depot 120 mg** Plus BSC *vs.* Placebo Plus BSC for **Tumor Control** in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, **Lung Neuroendocrine Tumors (NET)**

Study Design

Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung NET (N=216)

| Lanreotide (LAN) Autogel®/Depot 120 mg Plus BSC (N=144) *every 28 days until disease progression* | Placebo Plus BSC (N=72) *every 28 days until disease progression, then patient may enter open-label treatment with LAN 120 mg* |

Open-label Treatment
Patients who have not progressed after the 175 event cut-off reached

Follow-up Period
Patients who experienced disease progression during double-blind phase

Patients who experienced disease progression during open-label treatment

Does not request to enter or meet criteria for open-label treatment

Open-label Treatment
Patients who experienced disease progression during double-blind phase

Follow-up Period
Patients who experienced disease progression during open-label treatment

Does not request to enter or meet criteria for open-label treatment

Primary Endpoint	Progression-free survival (PFS), assessed by central review using RECIST v1.1 criteria
Secondary Endpoints	• Best overall response of complete response (CR) or partial response (PR) measured by RECIST v1.1 criteria • Overall survival • Time to treatment failure • Change from baseline in chromogranin A (CgA) • Change in quality of life (QoL), time to QoL deterioration • Safety and tolerability
Key Inclusion Criteria	• 18 years and older • Metastatic and/or unresectable pathologically confirmed well differentiated, typical or atypical neuroendocrine tumor of the lung • Histologic evidence of well differentiated NET of the lung (typical and atypical according to WHO criteria, evaluated locally) • A mitotic index <2 mitoses/2 mm² for typical carcinoid (TC) and <10 mitoses/2 mm² and/or foci of necrosis for a typical carcinoid (AC) • At least one measurable lesion of the disease on imaging (CT or MRI; RECIST v1.1) • Positive somatostatin receptor (SSTR) imaging
Key Exclusion Criteria	• Poorly differentiated or high grade carcinoma, or NET not of lung origin • Prior treatment with a somatostatin analog (SSA) at any time prior to randomization, except if that treatment was for <15 days of short acting SSA or one dose of long acting SSA and the treatment was received >6 weeks prior to randomization • Prior treatment with peptide receptor radionuclide therapy (PRRT) at any time prior to randomization • Prior treatment with >2 lines of cytotoxic chemotherapy or molecular targeted therapy or interferon for lung NET
Study sites	68 sites planned / 25 sites activated

For more information, please see https://clinicaltrials.gov/ct2/show/NCT02683941
The efficacy and safety of lanreotide in lung NET under investigation have not been established and it should not be used outside of clinical trials.
Job code: SOM-ALL-000313   January 2017

IPSEN
Innovation for patient care

Pfizer Oncology is committed to pursuing innovative treatments that have a meaningful impact on those living with cancer. As a leader in oncology speeding cures and accessible breakthrough medicines to patients, Pfizer Oncology is helping to redefine life with cancer. Our strong pipeline of biologics, small molecules and immunotherapies, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers. By working collaboratively with academic institutions, individual researchers, cooperative research groups, governments and licensing partners, Pfizer Oncology strives to cure or control cancer with its breakthrough medicines. Because Pfizer Oncology knows that success in oncology is not measured solely by the medicines you manufacture, but rather by the meaningful partnerships you make to have a more positive impact on people's lives.

PP-ONC-ESP-0027, date of preparation: February 2017

Personal

Tumours have specific characteristics and behaviours that may be best treated with personalised medicine. We're focused on transforming treatment by targeting the right drug at the right time for each patient.

Focused on what truly matters

SUG16/002   Date of preparation: January 2016.

Pfizer *Oncology*

Advanced Accelerator Applications (NASDAQ:AAAP) is an innovative radiopharmaceutical company that develops, produces and commercializes diagnostic and therapeutic molecular nuclear medicine, or MNM, products.

For over a decade, AAA has been at the forefront of developing predictive, preventive and personalized tools and procedures that have the potential to radically transform healthcare management both for healthcare professionals and patients. Our path to accomplishing this goal is by merging therapeutic and diagnostic approaches, and advancing early detection, treatment, and monitoring of diseases. AAA's focus on becoming a global leader within these categories supports its commitment to extending the lives of patients affected by serious or life threatening illnesses in the fields of oncology, neurology, cardiology and infectious & inflammatory diseases.

AAA currently has 22 production and research & development facilities that manufacture both diagnostic and therapeutic MNM products, and over 500 employees in 13 countries (Belgium, Canada, France, Germany, Israel, Italy, the Netherlands, Poland, Portugal, Spain, Switzerland, the UK and the US).

www.adacap.com

NET – from contemporary clinical management to controversis and new frontiers

Neuroendocrine Tumors: A Multidisciplinary Approach

Editors
Mauro Papotti
Wouter W. de Herder

The term 'carcinoid' entered medical literature over 100 years ago to describe a peculiar intestinal epithelial neoplasm. Since then, a large body of literature has expanded the concept of carcinoid, later replaced by the term 'NeuroEndocrine Tumor' (NET), defining a wide spectrum of peculiar tumors, potentially affecting all organs and tissues, originating from neuroendocrine cells, sharing, but, at the same time, keeping, pathognomonic pathological, radiological and clinical features.

This book provides an authoritative overview of the epidemiological, clinical, genetic, molecular and pathological characteristics of NETs and highlights the most relevant controversial issues in the classification, diagnosis and therapy. Furthermore the new frontiers in the field of medical therapies are presented, through a multidisciplinary and translational approach. Considering the fact that NETs have been recently demonstrated less rare as considered so far, *Neuroendocrine Tumors: A Multidisciplinary Approach* is a must read for endocrinologists, gastroenterologists, endocrine surgeons, as well as pathologists, nuclear medicine physicians and radiologists focused on NET.

Contents

Preface: **Papotti, M.; de Herder, W.W.; Ghigo, E.; Guaraldi, F.**

- Epidemiology of Neuroendocrine Tumors: **Fraenkel, M.; Faggiano, A.; Valk, G.D.**
- Biochemical Testing in Patients with Neuroendocrine Tumors: **Granberg, D.**
- Clinical Syndromes Related to Gastrointestinal Neuroendocrine Neoplasms: **Boutzios, G.; Kaltsas, G.**
- Radiological Imaging: Computed Tomography, Magnetic Resonance Imaging and Ultrasonography: **Sundin, A.; Wills, M.; Rockall, A.**
- Nuclear Medicine Imaging of Neuroendocrine Tumors: **Brabander, T.; Kwekkeboom, D.J.; Feelders, R.A.; Brouwers, A.H.;Teunissen, J.J.M.**
- Endoscopy and Endoscopic Ultrasound in Assessing and Managing Neuroendocrine Neoplasms: **O'Toole, D.; Palazzo, L.**
- Pathology: Classification and Immunoprofile: **Blank, A.; Schmitt, A.; Perren, A.**
- Genetics and Epigenetics of Pancreatic Neuroendocrine Tumors and Pulmonary Carcinoids: **Dreijerink, K.M.A. ; Derks, J.L.; Cataldo, I.; Scarpa, A.; Valk, G.D.; Speel, E.-J.M.**
- Pancreatic Surgery: **Maurizi, A.; Partelli, S.; Falconi, M.**
- Gastrointestinal Surgery of Neuroendocrine Neoplasms: **Palnæs Hansen, C.; Holst Olsen, I.; Knigge, U.**
- Transplantation and Debulking Procedures for Neuroendocrine Tumors: **Frilling, A.; Al-Nahhas, A.; Clift, A.K.**
- A 25-Year Experience of Gastroenteropancreatic Neuroendocrine Tumors and Somatostatin (Congeners) Analogs: From Symptom Control to Antineoplastic Therapy: **O'Dorisio, T.M.; Anthony, L.B.**
- Medical Therapy of Pulmonary Neuroendocrine Neoplasms: Targeted, Symptomatic and Chemotherapy: **Ferolla, P.**
- Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: **Bodei, L.; Kidd, M ; Prasad, V.; Modlin, I.M.**
- Hormone and Receptor Candidates for Target and Biotherapy of Neuroendocrine Tumors: **Hofland, L.J.; Vandamme, T.; Albertelli, M.; Ferone, D.**
- The Role of Chemotherapy in Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: **Strosberg, J.; Goldman, J.; Costa, F.; Pavel, M.**
- Other Novel Therapies: Biomarkers, microRNAs and microRNA Inhibitors, DNA Methylation, Epigenetics, Immunotherapy and Virotherapy: **Giandomenico, V.; Thirlwell, C.; Essand, M.**

Author Index/Subject Index

The easiest way to order: **www.karger.com/fhore**

KARGER 125

SAVE THE DATE

ENETS Centers of Excellence (CoE) Academy Fellowship Grant (EAFG) Application:
- Submission begins 1 May 2017
- Submission ends 30 June 2017

15th Annual ENETS Conference, 7- 9 March 2018, Barcelona, Spain:
- ENETS Early Bird Registration begins 1 September 2017
- ENETS Early Bird Registration ends 30 November 2017
- ENETS Regular Registration begins 1 December 2017
- ENETS Regular Registration ends 11 February 2018

ENETS Abstract Submission for the 15th Annual ENETS Conference:
- Submission begins 1 September 2017
- Submission ends 3 December 2017

15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease

7 - 9 March 2018 | Barcelona | Spain

ENETS Travel Grant Submission for the 15th Annual ENETS Conference:
- Submission begins 1 September 2017
- Submission ends 3 December 2017

ENETS Grants and Awards Application:
- Submission begins 1 November 2017
- Submission ends 7 January 2018

  - ENETS CoE Training Fellowship Grant
  - ENETS CoE Young Investigator Grant
  - ENETS Translational Grant - partially industry - sponsored
  - ENETS Hakan Ahlman Award

๑ NOVARTIS

Novartis Oncology has emerged as a global leader in oncology by consistently discovering, developing, and making available novel therapies that help to transform outcomes for people living with cancer and targeted diseases.

We share a common goal with the global oncology community to improve and extend the lives of patients. Through open partnerships with the community, we gain insights and build knowledge, driving clinical development based on scientific and patient insights.

Our research is driven by a distinctive scientific and clinical strategy, focusing on unmet medical needs and disease pathways. A robust R&D program has enabled us to offer a wide range of innovative therapies to meet patient needs. We have one of the broadest oncology pipelines in the industry, with more than 20 compounds in various stages of development.

For more information about how we are transforming the treatment of cancer and other diseases, visit **www.novartisoncology.com**.

๑ NOVARTIS

Novartis Oncology

Inspired by Patients, Driven to Make a Difference

A lasting legacy in NET

With experience that extends nearly 3 decades, we have a long heritage in the research, development, and discovery of neuroendocrine tumors (NET) treatments

An unwavering commitment to patients with NET

With two approved products for the treatment of select NET, we are transforming outcomes for patients suffering from this type of cancer

A focus on NET innovation

At Novartis, we are dedicated to the research and development of innovative products in NET

ʊ **NOVARTIS**

ENETS *European Neuroendocrine Tumor Society*

APPROACHING ONCOLOGY FROM A DIFFERENT DIMENSION

Ipsen has a strong heritage in oncology. Success is comprised of experience, vision and passion.

Like a master watchmaker, we are focused on innovation and precision for new therapeutic options in oncology.

We remain committed to developing effective and innovative therapeutic solutions to improve treatment outcomes for patients and to support healthcare professionals in their daily practice.

IPSEN Innovation for patient care

TAILORED ONCOLOGY